[go: up one dir, main page]

US5102667A - Isoindolone derivatives, their preparation and the pharmaceutical compositions containing them - Google Patents

Isoindolone derivatives, their preparation and the pharmaceutical compositions containing them Download PDF

Info

Publication number
US5102667A
US5102667A US07/616,262 US61626290A US5102667A US 5102667 A US5102667 A US 5102667A US 61626290 A US61626290 A US 61626290A US 5102667 A US5102667 A US 5102667A
Authority
US
United States
Prior art keywords
7ars
3ars
radical
diphenyl
perhydroisoindolone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US07/616,262
Other languages
English (en)
Inventor
Marie-Christine Dubroeucq
Claude Moutonnier
Jean-Francois Peyronel
Michel Tabart
Alain Truchon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhone Poulenc Sante SA
Original Assignee
Rhone Poulenc Sante SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Sante SA filed Critical Rhone Poulenc Sante SA
Assigned to RHONE-POULENC SANTE, reassignment RHONE-POULENC SANTE, ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: DUBROEUCQ, MARIE-CHRISTINE, MOUTONNIER, CLAUDE, PEYRONEL, JEAN-FRANCOIS, TABART, MICHEL, TRUCHON, ALAIN
Application granted granted Critical
Publication of US5102667A publication Critical patent/US5102667A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to new isoindolone derivatives of general formula: ##STR2## and their salts where such exist, which antagonize the effects of substance P and by virtue of this fact are particularly valuable in the therapy fields where this substance is known to be involved.
  • radicals R are identical and represent hydrogen atoms or together form a bond
  • R' are identical and represent phenyl radicals optionally substituted by a halogen atom or by a methyl radical in position 2 or 3,
  • X represents an oxygen or sulphur atom or a radical N-R 3 , for which R 3 is a hydrogen atom, an alkyl radical containing 1 to 12 carbon atoms and optionally substituted [by one or more carboxyl, dialkylamino, acylamino, alkoxycarbonyl, alkoxycarbonylamino, carbamoyl, alkylcarbamoyl or dialkylcarbamoyl (the alkyl portions of these radicals being able themselves to carry a dialkylamino or phenyl substituent by phenyl, substituted phenyl (substituted by halogen, alkyl, alkoxy or dialkylamino), naphthyl, thienyl, furyl, pyridyl or imidazolyl radicals] or a dialkylamino radical,
  • R 1 represents a phenyl radical optionally substituted by one or more halogen atoms or hydroxyl or alkyl radicals which can optionally be substituted (by halogen atoms or amino, alkylamino or dialkylamino radicals) or alkoxy or alkylthio radicals, which can optionally be substituted (by hydroxyl or dialkylamino radicals in which the alkyl parts can form, with the nitrogen atom to which they are attached, a 5- to 6-membered heterocycle which can contain another hetero-atom chosen from oxygen, sulphur or nitrogen, optionally substituted by an alkyl radical), or substituted by amino, alkylamino or dialkylamino radicals in which the alkyl parts can form, with the nitrogen atom to which they are attached, a heterocycle as defined above, or represents a cyclohexadienyl or naphthyl radical or a saturated or unsaturated monocyclic or polycyclic heterocycle containing 5 to 9 carbon atom
  • R 2 represents a hydrogen or halogen atom or a hydroxyl, alkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxy, alkylthio, acyloxy, carboxyl, alkoxycarbonyl, dialkylaminoalkoxycarbonyl, benzyloxycarbonyl, amino, acylamino or alkoxycarbonylamino radical.
  • alkyl or acyl radicals contain 1 to 4 carbon atoms in a straight or branched chain.
  • R' carries a halogen substituent
  • the latter can be chosen from chlorine or fluorine.
  • R 1 or R 3 contains a halogen atom
  • the latter can be chosen from chlorine, bromine, fluorine or iodine.
  • R 1 represents a saturated or unsaturated monocyclic or polycyclic heterocyclic radical it can be chosen, by way of example, from thienyl, furyl, pyridyl, dithiinyl, indolyl, isoindolyl, thiazolyl, isothiazolyl, oxazolyl, imidazolyl, pyrrolyl, triazolyl, thiadiazolyl, quinolyl, isoquinolyl or naphthyridinyl.
  • the products of general formula (I) have various stereoisomer forms and it is understood that the isoindolone derivatives in the (3aR,7aR) form in the pure state, or in the form of a mixture of the cis forms (3aRS,7aRS), fall within the scope of the present invention.
  • the symbol R 2 is other than a hydrogen atom
  • the substituted chain on the isoindolone has a chiral center and it is understood that the enantiomer forms and their mixtures also fall within the scope of the present invention.
  • the isoindolone derivatives of general formula (I) can be obtained by the action of the acid of general formula: ##STR4## or of a reactive derivative of this acid, in which R 1 and R 2 are defined as above, on an isoindole derivative of general formula: ##STR5## in which the symbols R and R' are defined as above, followed, if necessary, by the conversion of the amide obtained to the thioamide or to an amidine for which X represents a radical N-R 3 , R 3 having the definition given above.
  • amino, alkylamino or carboxyl radicals contained in R 1 and/or R 2 are preferably protected beforehand.
  • the protection is effected by any compatible group, the positioning and the removal of which have no effect on the remainder of the molecule.
  • the methods described by T. W. Greene, Protective Groups in Organic Synthesis, by A. Wiley - Interscience Publication (1981), or by McOmie, Protective Groups in Organic Chemistry, Plenum Press (1973) are used.
  • the amino or alkylamino groups can be protected by the following radicals: methoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl, allyloxycarbonyl, vinyloxycarbonyl, trichloroethoxycarbonyl, trichloroacetyl, trifluoroacetyl, chloroacetyl, trityl, benzhydryl, benzyl, allyl, formyl, acetyl, benzyloxycarbonyl or its substituted derivatives; and
  • the acid groups can be protected by the following radicals: methyl, ethyl, t-butyl, benzyl, substituted benzyl or benzhydryl.
  • R 2 represents a hydroxyl radical it is preferable to protect this radical beforehand.
  • the protection is effected, for example, by an acetoxy, trialkylsilyl or benzyl radical, or in the form of a carbonate by a radical --COORa, in which Ra is an alkyl or benzyl radical.
  • the reaction is generally carried out in the presence of a condensing agent such as a carbodiimide [for example dicyclohexylcarbodiimide or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide], N,N'-carbonyldiimidazole or 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline, in an organic solvent such as a chlorinated solvent (dichloromethane, dichloroethane or chloroform, for example), an ether (tetrahydrofuran or dioxane, for example), an ester (ethyl acetate, for example), an amide (dimethylacetamide or dimethylformamide, for example), a nitrile
  • a condensing agent such as a carbodiimide [for example dicyclohexylcarbodiimide or 1-(3-dimethylaminopropyl)-3-ethyl
  • the reaction is advantageously carried out by means of an acid chloride, an anhydride, a mixed anhydride or a reactive ester in which the ester radical is a succinimido, 1-benzotriazolyl, 4-nitrophenyl, 2,4-dinitrophenyl, pentachlorophenyl or phthalimido radical.
  • the reaction generally takes place at a temperature of between -40° and +40° C., in an organic solvent, such as a chlorinated solvent (dichloromethane, dichloroethane or chloroform, for example), an ether (tetrahydrofuran or dioxane, for example), an amide (dimethylacetamide or dimethylformamide, for example) or a ketone (acetone, for example) or in a mixture of these solvents, in the presence of an acid acceptor, such as a nitrogen-containing organic base, such as, for example, pyridine, dimethylaminopyridine, N-methylmorpholine or a trialkylamine (in particular triethylamine) or such as an epoxide (propylene oxide, for example) or a carbodiimide, or in an aqueous/organic medium, in the presence of an alkaline condensing agent such as sodium bicarbonate, and, if necessary, the amide obtained is converted to a
  • the reaction is carried out by the action of Lawesson's reagent [2,4-bis(4-methoxyphenyl)-2,4-dithioxo-1,3,2,4-dithiadiphosphetane] or by the action of phosphorus pentasulphide, in an organic solvent, such as an ether (tetrahydrofuran, 1,2-dimethoxyethane or dioxane, for example) or an aromatic hydrocarbon (toluene, for example), at a temperature between 0° C. and the reflux temperature of the reaction mixture.
  • an organic solvent such as an ether (tetrahydrofuran, 1,2-dimethoxyethane or dioxane, for example) or an aromatic hydrocarbon (toluene, for example)
  • R 3 is defined as above.
  • the preparation of the isoindolium derivative of general formula (IV) in which Y is a chlorine atom or a methoxy or ethoxy radical takes place by the action of a reagent such as phosgene, phosphorus oxychloride, phosphorus pentachloride, thionyl chloride, oxalyl chloride, trichloromethyl chloroformate, triethyl(or trimethyl)oxonium tetrafluoborate, methyl(or ethyl) triflate, methyl(or ethyl) fluorosulphonate or methyl(or ethyl) sulphate.
  • a reagent such as phosgene, phosphorus oxychloride, phosphorus pentachloride, thionyl chloride, oxalyl chloride, trichloromethyl chloroformate, triethyl(or trimethyl)oxonium tetrafluo
  • the preparation of the isoindolium derivative of general formula (IV) in which Y is a chlorine atom or a methyl(or ethyl)thio, benzylthio or alkoxycarbonylmethylthio radical takes place using the isoindolone derivative of general formula (I) in which X is a sulphur atom as the starting material, by the action of a reagent such as mentioned above or by the action of methyl, ethyl or benzyl bromide or iodide.
  • the reaction takes place in a chlorinated solvent (dichloromethane or dichloroethane, for example) or in an aromatic hydrocarbon (toluene, for example), at a temperature between 0° C.
  • the isoindolone derivatives of general formula (I) in which R 1 and R 2 are defined as above, with the exception of representing or carrying hydroxyl, amino, alkylamino, dialkylamino or carboxyl substituents, and R, R', R 3 and X are defined as above can also be obtained from a cyclohexenone derivative of general formula: ##STR7## in which R and R' are defined as above, by the action of 1,3,5-tris-trimethylsilylmethyl-1,3,5-triazine and an acid fluoride of general formula: ##STR8## in which R 1 and R 2 are defined as above, followed, if necessary, by the conversion of the amide obtained to a thioamide or to an amidine for which X represents a radical N-R 3 having the definition given above.
  • the reaction generally takes place in an organic solvent, such as a chlorinated solvent (dichloroethane or trichloroethane, for example) or in an aromatic hydrocarbon (toluene or xylene, for example), at a temperature between 80° C. and the reflux temperature of the reaction mixture.
  • organic solvent such as a chlorinated solvent (dichloroethane or trichloroethane, for example) or in an aromatic hydrocarbon (toluene or xylene, for example
  • the isoindolone derivatives of general formula (I) for which the symbol R 1 is an alkoxyphenyl radical in which the alkyl part is substituted or unsubstituted and the symbol R 2 is other than a hydroxyl radical can also be prepared from an isoindole derivative of general formula (I) for which R 1 is a hydroxyphenyl radical, by the action, in a basic medium, of the corresponding halogenated derivative, of general formula:
  • Hal is a halogen atom and R 4 is an alkyl radical optionally substituted by a hydroxyl radical, or dialkylamino in which the alkyl parts can optionally form, with the nitrogen atom to which they are attached, a heterocycle as defined in general formula (I).
  • the reaction generally takes place in the presence of a base, such as a hydride, an alkali metal hydroxide, an alkali metal alcoholate or an alkali metal carbonate, in an organic solvent, such as an amide (dimethylformamide, for example), an aromatic hydrocarbon (toluene, for example) or a ketone (butanone, for example) or in a mixture of these solvents, at a temperature between 20° C. and the reflux temperature of the reaction mixture.
  • a base such as a hydride, an alkali metal hydroxide, an alkali metal alcoholate or an alkali metal carbonate
  • organic solvent such as an amide (dimethylformamide, for example), an aromatic hydrocarbon (toluene, for example) or a ketone (butanone, for example) or in a mixture of these solvents
  • isoindolone derivatives of general formula (I) for which X is a radical N-R 3 can also be obtained from the isoindolone derivative of general formula (III) by the action of a product of general formula: ##STR9## optionally in the form of a salt, in which R 1 , R 2 and R 3 are defined as above and R 5 represents an alkoxy radical containing 1 to 4 carbon atoms in a straight or branched chain or a methylthio, ethylthio, benzylthio or alkoxycarbonylmethylthio radical, or, if R 3 is other than a hydrogen atom, R 5 represents an acyloxy radical containing 1 to 4 carbon atoms or a chlorine atom.
  • the reaction is carried out using the derivative of general formula (IX), optionally prepared in situ, in an organic solvent, such as a chlorinated solvent (dichloromethane or dichloroethane, for example), an ether (tetrahydrofuran, for example), an aromatic hydrocarbon (toluene, for example) or a nitrile, for example acetonitrile, at a temperature between 0° C. and the reflux temperature of the reaction mixture.
  • a chlorinated solvent dichloromethane or dichloroethane, for example
  • an ether tetrahydrofuran, for example
  • an aromatic hydrocarbon toluene, for example
  • a nitrile for example acetonitrile
  • the isoindole derivative of general formula (III) can be obtained from the corresponding derivative of general formula: ##STR10## in which R and R' are defined as above and R 6 represents an allyl radical or a radical of structure --CR a R b R c , in which R a and R b are hydrogen atoms or phenyl radicals, which are optionally substituted (by a halogen atom or an alkyl, alkoxy or nitro radical), and R c is defined as R a and R b or represents an alkyl or alkoxyalkyl radical, at least one of R a , R b and R c being a substituted or unsubstituted phenyl radical and the alkyl radicals containing 1 to 4 carbon atoms in a straight or branched chain, by removal of the radical R 6 by any known method which does not affect the remainder of the molecule.
  • R when R is a hydrogen atom and when R 6 is other than an allyl radical, the group R 6 can be removed by catalytic hydrogenation in the presence of palladium.
  • the reaction takes place in an acid medium, in a solvent such as an alcohol (methanol or ethanol), in water or directly in acetic acid or formic acid, at a temperature between 20° and 60° C.
  • R 6 is a benzhydryl or trityl radical
  • the removal can be effected by treatment in an acid medium, working at a temperature between 0° C. and the reflux temperature of the reaction mixture, in an alcohol, in an ether, in water or directly in acetic acid, formic acid or trifluoroacetic acid.
  • the group R 6 can also be removed by the action of vinyl chloroformate, 1-chloroethyl chloroformate or phenyl chloroformate, a product of general formula: ##STR11## in which R and R' are defined as above and R 7 is a vinyl, 1-chloroethyl or phenyl radical, being formed as an intermediate, followed by removal of the radical R 7 by acid treatment.
  • the action of the chloroformate generally takes place in an organic solvent, such as a chlorinated solvent (dichloromethane, dichloroethane or chloroform, for example), an ether (tetrahydrofuran or dioxane, for example) or a ketone (acetone, for example) or in a mixture of the solvents, the reaction being carried out at a temperature between 20° C. and the reflux temperature of the reaction mixture.
  • a chlorinated solvent dichloromethane, dichloroethane or chloroform, for example
  • an ether tetrahydrofuran or dioxane, for example
  • ketone acetone
  • the removal of the radical R 7 is effected by treatment in an acid medium, for example by trifluoroacetic acid, formic acid, methanesulphonic acid, p-toluenesulphonic acid, hydrochloric acid or hydrobromic acid, in a solvent, such as an alcohol, an ether, an ester, a nitrile or a mixture of these solvents or in water, at a temperature between 0° C. and the reflux temperature of the reaction mixture.
  • an acid medium for example by trifluoroacetic acid, formic acid, methanesulphonic acid, p-toluenesulphonic acid, hydrochloric acid or hydrobromic acid
  • a solvent such as an alcohol, an ether, an ester, a nitrile or a mixture of these solvents or in water, at a temperature between 0° C. and the reflux temperature of the reaction mixture.
  • the isoindolone derivative of general formula (III) is obtained in the form of a salt of the acid employed, which salt can be used directly in the subsequent step.
  • the isoindolone derivative of general formula (X) can be obtained by a cycloaddition reaction by the action of a silyl derivative of general formula: ##STR12## in which R 6 is defined as above, (R o ) 3 represents alkyl radicals or alkyl and phenyl radicals and R oo represents an alkoxy, cyano or phenylthio radical, on the cyclohexenone derivative of general formula (VI).
  • the reaction is carried out in the presence of a catalytic amount of an acid chosen from trifluoroacetic acid, acetic acid, methanesulphonic acid or the acids mentioned in the undermentioned references, in an organic solvent, such as a chlorinated solvent (dichloromethane or dichloroethane, for example), in an aromatic hydrocarbon, in a nitrile (acetonitrile) or in an ether, at a temperature between 0° C. and the reflux temperature of the reaction mixture.
  • an organic solvent such as a chlorinated solvent (dichloromethane or dichloroethane, for example)
  • an aromatic hydrocarbon in a nitrile (acetonitrile) or in an ether, at a temperature between 0° C. and the reflux temperature of the reaction mixture.
  • silyl derivative of general formula (XII) can be obtained by the methods described by:
  • isoindolone derivatives of general formula (III) and (X) have several stereoisomer forms.
  • the separation of the isomer forms is preferably carried out at the level of the derivative of general formula (III). The separation takes place by any known method compatible with the molecule.
  • the separation can be effected by preparation of an optically active salt, by the action of L(+)- or D(-)- mandelic acid or of dibenzoyltartaric acid followed by separation of the isomers by crystallization.
  • the desired isomer is liberated from its salt in a basic medium.
  • the new isoindolone derivatives of general formula (I) can be purified, if necessary, by physical methods such as crystallization or chromatography.
  • the new derivatives of general formula (I) for which the symbols R 1 and/or R 2 contain amino or alkylamino substituents and/or X represents a radical NR 3 can be converted to addition salts with acids.
  • addition salts with pharmaceutically acceptable acids are the salts formed with inorganic acids (hydrochlorides, hydrobromides, sulphates, nitrates or phosphates) or with organic acids (succinates, fumarates, tartrates, acetates, propionates, maleates, citrates, methanesulphonates, p-toluenesulphonates or isethionates) or with substituted derivatives of these compounds.
  • the new isoindolone derivatives of general formula (I) can also, if necessary, when R 2 represents a carboxyl radical, be converted to metal salts or to addition salts with a nitrogenous base, by the methods known per se.
  • These salts can be obtained by the action of a metal (for example alkali metal or alkaline earth metal) base, ammonia or an amine on a product according to the invention, in an appropriate solvent, such as an alcohol, an ether or water, or by exchange reaction with a salt of an organic acid.
  • the salt formed precipitates, after concentration of the solution if necessary, and is separated off by filtration, settling or lyophilization.
  • salts with the alkali metals sodium, potassium or lithium
  • alkaline earth metals magnesium or calcium
  • ammonium salt and the salts of nitrogenous bases ethanolamine, diethanolamine, trimethylamine, triethylamine, methylamine, propylamine, diisopropylamine, N,N-dimethylethanolamine, benzylamine, dicyclohexylamine, N-benzyl- ⁇ -phenethylamine, N,N'-dibenzylethylenediamine, diphenylenediamine, benzhydrylamine, quinine, choline, arginine, lysine, leucine or dibenzylamine).
  • nitrogenous bases ethanolamine, diethanolamine, trimethylamine, triethylamine, methylamine, propylamine, diisopropylamine, N,N-dimethylethanolamine, benzylamine, dicyclohexylamine, N-benzyl- ⁇ -phenethylamine,
  • the new isoindolone derivatives according to the present invention which antagonize the effects of substance P can find application in the fields of analgesia, inflammation, asthma and allergies, on the central nervous system, on the cardiovascular system, as an antispasmodic agent, or on the immune system, as well as in the field of stimulation of lachrymal secretions.
  • the products according to the invention show an affinity for the substance P receptors at doses of between 5 and 2,000 nM according to the technique described by C. M. Lee et al., Mol. Pharmacol., 23, 563-69 (1983).
  • Substance P and pain an updating, J. L. Henry, TINS, 3 (4), 97 (1980);
  • Substance P plays a role in the modulation of immune processes (J. P. McGillis et al., Fed. Proc., 46 (1), 196-199 (1987)). Substance P binds to receptors of human cells in cultures: the lymphoblasts of line IM 9 [D. G. Payan et al., J. of Immunology, 133 (6), 3260-5 (1984)]. The products according to the invention displace substance P at these locations.
  • the isoindolone derivatives according to the present invention are not toxic; they have been shown to be atoxic in mice, administered subcutaneously in a dose of 40 mg/kg or orally in a dose of 100 mg/kg.
  • radicals R are identical and represent hydrogen atoms or together form a bond
  • R' are identical and represent phenyl radicals optionally substituted by a fluorine or chlorine atom or by a methyl radical in position 2 or 3,
  • X represents an oxygen or sulphur atom or a radical N-R 3 for which R 3 is a hydrogen atom, an alkyl radical containing 1 to 12 carbon atoms and optionally substituted [by one or more carboxyl, dialkylamino, acylamino, alkoxycarbonyl, alkoxycarbonylamino, carbamoyl, alkylcarbamoyl or dialkylcarbamoyl radicals (the alkyl portions of these radicals being able themselves to carry a dialkylamino or phenyl substitutent) or substituted by phenyl, substituted phenyl (substituted by a fluorine or chlorine atom or by an alkyl, alkoxy or dialkylamino radical), naphthyl, 2-thienyl, 2-furyl, pyridyl or imidazolyl radicals] or a dialkylamino radical,
  • R 1 represents a phenyl radical optionally substituted by one or more fluorine, chlorine or bromine atoms or hydroxyl radicals, or alkyl radicals, which can optionally be substituted (by halogen atoms or amino radicals), or alkoxy or alkylthio radicals, which can optionally be substituted (by hydroxyl or dialkylamino radicals in which the alkyl parts can form, with the nitrogen atom to which they are attached, a 6-membered heterocycle which can contain another nitrogen atom optionally substituted by an alkyl radical), or substituted by amino, alkylamino or dialkylamino radicals, in which the alkyl parts can form, with the nitrogen atom to which they are attached, a saturated 5- or 6-membered heterocycle, which can also contain another oxygen atom, or represents a cyclohexadienyl or naphthyl radical or a saturated or unsaturated monocyclic or polycyclic heterocyclic radical containing 5 to 9 carbon atom
  • R 2 represents a hydrogen or fluorine atom or a hydroxyl, alkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, alkoxy, alkylthio, acyloxy, carboxyl, alkoxycarbonyl, dialkylaminoalkoxycarbonyl, benzyloxycarbonyl, amino, acylamino or alkoxycarbonylamino radical, the abovementioned alkyl and acyl radicals being straight-chain or branched and containing 1 to 4 carbon atoms.
  • N,N'-Carbonyldiimidazole (1.7 g) is added to a solution of phenylacetic acid (1.34 g) in dry dichloromethane (30 cc) cooled to +5° C. The mixture is stirred for 1 hour at +5° C. and a solution of 7,7-diphenyl-4-perhydroisoindolone hydrochloride (3.27 g) and triethylamine (1.7 cc) in dichloromethane (30 cc) is then added. The reaction mixture is stirred for 1 hour at +5° C. and then for 1 hour at 20° C.
  • reaction mixture is washed with a saturated aqueous solution (50 cc) of sodium bicarbonate, dried over magnesium sulphate and filtered and the filtrate is concentrated to dryness under reduced pressure (2.7 kPa).
  • the residue is crystallized from acetonitrile (15 cc).
  • the crystals are drained, washed with isopropyl ether (10 cc) and dried.
  • (3aRS,7aRS)-7,7-diphenyl-2-(phenylacetyl)-4-perhydroisoindolone (2.7 g) melting at 216° C. is obtained.
  • (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone hydrochloride can be prepared by one of the following methods:
  • (3aRS,7aRS)-7,7-diphenyl-2-vinyloxycarbonyl-4-perhydroisoindolone (177 g) is treated with a 5.7N solution (1,000 cc) of hydrochloric acid in dry dioxane for 30 minutes at 20° C. The solution is concentrated to dryness under reduced pressure (2.7 kPa) and the residue is taken up in ethanol (500 cc) and the reaction mixture is stirred at 60° C. for 30 minutes and then cooled to +5° C. The crystals obtained are drained, washed with ethanol (50 cc) and dried. (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (130 g) melting at 270° C. is obtained.
  • Trifluoroacetic acid (5 drops) is added to a solution of 4,4-diphenyl-cyclohex-2-en-1-one (155 g) and N-butoxymethyl-N-trimethylsilylmethyl-benzylamine (202 cc) in dry dichloromethane (1,000 cc) and the reaction mixture is refluxed for 45 minutes.
  • N-Butoxymethyl-N-trimethylsilylmethyl-benzylamine (50 cc) and trifluoroacetic acid (3 drops) are added and the mixture is stirred for a further 45 minutes under reflux before adding further N-butoxymethyl-N-trimethylsilylmethyl-benzylamine (25 cc) and trifluoroacetic acid (3 drops).
  • reaction mixture is stirred under reflux for 45 minutes and then treated with potassium carbonate (50 g) and filtered and the filtrate is concentrated to dryness under reduced pressure (2.7 kPa).
  • the residue is dissolved in isopropyl ether (200 cc) and the solution is cooled at 0° C. for 1 hour.
  • the crystals are drained, washed with isopropyl ether (2 * 15 cc) and dried to give (3aRS,7aRS)-2-benzyl-7,7-diphenyl-4-perhydroisoindolone (193 g) in the form of white crystals melting at 132° C.
  • N-Butoxymethyl-N-trimethylsilylmethyl-benzylamine can be prepared by the method of Y. Terao et al., Chem. Pharm. Bull., 33, 2762 (1985).
  • a solution of L(+)-mandelic acid (92.8 g) in ethyl acetate (1,000 cc) is added to the solution thus obtained, with stirring; after stirring for 4 hours, the crystals obtained are drained, washed with ethyl acetate (2 * 250 cc) and dried.
  • the crystals are taken up in distilled water (2,000 cc); the mixture is refluxed, with stirring, for 15 minutes; the insoluble crystals are drained, washed with distilled water (2 * 100 cc) and dried.
  • 2,4-Bis-(4-methoxyphenyl)-2,4-dithioxo-1,3,2,4-dithiadiphosphetane (3.95 g) is added to a solution of (3aRS,7aRS)-7,7-diphenyl-2-phenylacetyl-4-perhydroisoindolone (4 g) in tetrahydrofuran (160 cc); stirring of the reaction mixture is continued for 20 hours at ambient temperature.
  • the reaction mixture is treated with a 20% aqueous ammonia solution (10 cc) and with distilled water (30 cc) and is then extracted with ethyl acetate (2 * 150 cc); the organic phases are combined and washed with distilled water (2 * 200 cc) and with a saturated aqueous solution (100 cc) of calcium chloride, dried over magnesium sulphate and concentrated to dryness under reduced pressure (2.7 kPa).
  • the residue is chromatographed on a silica gel column (0.06-0.2 mm, diameter 3 cm, height 30 cm) eluting with a mixture of cyclohexane and ethyl acetate (50/50 by volume), recovering 25 cc fractions.
  • Triethyloxonium tetrafluoborate (10.45 g) is added to a solution of (3aRS,7aRS)-7,7-diphenyl-2-phenylacetyl-4-perhydroisoindolone (20 g) in dichloromethane (50 cc). Stirring of the reaction mixture is continued for 20 hours at ambient temperature.
  • a 0.8N solution (8.8 cc) of dichloromethane in ammonia is added to a stirred suspension of (3aRS,7aRS)-2-[(1ethoxy-2-phenyl)ethylidene]-4-oxo-7,7-diphenyl-perhydroisoindolium tetrafluoborate (3.75 g) in anhydrous dichloromethane (30 cc), which is cooled to -20° C. The temperature of the reaction mixture is allowed to return to ambient temperature and stirring is continued for 5 hours. The reaction mixture is treated with a 10% aqueous solution (30 cc) of potassium carbonate.
  • Methylamine (0.43 cc) is added to a stirred suspension of (3aRS,7aRS)-2-[(1-ethoxy-2-phenyl)-ethylidene]-4-oxo-7,7-diphenyl-perhydroisoindolium tetrafluoborate (3 g), prepared according to Example 4, in anhydrous dichloromethane (5 cc). Stirring of the reaction mixture is continued for 3 hours at ambient temperature; the reaction mixture is diluted with dichloromethane (40 cc) and treated with an aqueous solution (15 cc) containing potassium carbonate (22 g).
  • the precipitate present is removed by filtration and the organic phase is then washed with distilled water (15 cc) and with a saturated aqueous solution (10 cc) of sodium chloride, dried over magnesium sulphate and concentrated to dryness under reduced pressure (2.7 kPa).
  • Ethylamine (0.3 cc) is added to a stirred suspension of (3aRS,7aRS)-2-[(1-ethoxy-2-phenyl)ethylidene]-4-oxo-7,7-diphenyl-perhydroisoindolium tetrafluoroborate (3 g), prepared in accordance with Example 4, in anhydrous dichloromethane (5 cc). Stirring of the reaction mixture is continued for 20 hours at ambient temperature. The precipitate obtained is drained, washed with ethyl ether (30 cc) and dried.
  • Propylamine (0.6 cc) is added to a stirred suspension of (3aRS,7aRS)-2-[(1-ethoxy-2-phenyl)-ethylidene]-4-oxo-7,7-diphenyl-perhydroisoindolium tetrafluoborate (3.5 g), prepared in accordance with Example 4, in anhydrous dichloromethane (30 cc), which is cooled to +5° C. Stirring of the reaction mixture is continued for 20 hours at ambient temperature; the reaction mixture is treated with a 10% aqueous solution (30 cc) of potassium carbonate.
  • 2-N,N-Dimethylaminoethylamine (0.77 cc) is added to a stirred suspension of (3aRS,7aRS)-2-[(1-ethoxy-2-phenyl)ethylidene]-4-oxo-7,7-diphenyl-perhydroisoindolium tetrafluoborate (3.75 g), prepared in accordance with Example 4, in anhydrous dichloromethane (30 cc), which is cooled to +5° C. Stirring of the reaction mixture is continued for 20 hours at ambient temperature. The reaction mixture is treated with a 10% aqueous solution (30 cc) of potassium carbonate.
  • the precipitate present is removed by filtration and the organic phase is then washed with distilled water (15 cc) and with a saturated aqueous solution (15 cc) of sodium chloride, dried over magnesium sulphate and concentrated to dryness under reduced pressure (2.7 kPa).
  • the residue is crystallized from acetonitrile (5 cc).
  • the crystals obtained are drained and dried. They are recrystallized from acetonitrile (6 cc).
  • the crystals obtained are drained and dried.
  • 6-Acetylaminohexylamine (0.63 g) is added to a suspension of (3aRS,7aRS)-2-[(1-ethoxy-2-phenyl)-ethylidene]-4-oxo-7,7-diphenyl-perhydroisoindolium tetrafluoborate (2.1 g) in anhydrous dichloromethane (15 cc).
  • the reaction mixture is stirred for 16 hours at 20° C. and then diluted with a 20% aqueous solution (50 cc) of potassium carbonate and dichloromethane (50 cc), stirred and then filtered.
  • Infrared spectrum characteristic bands in cm -1 : 3290, 3100-3000, 3000-2825, 1715, 1655, 1615, 1600, 1580, 1495, 1550, 750, 700.
  • a solution of iodomethane (20 g) in acetone (200 cc) is added to a solution of (3aRS,7aRS)-7,7-diphenyl-2-(2-phenylthioacetyl)-4-perhydroisoindolone (20 g) in acetone (150 cc).
  • the reaction mixture is stirred at +50° C. for 20 hours.
  • the precipitate obtained is drained, washed with isopropyl ether and dried.
  • 6-Acetylaminohexylamine (0.63 g) is added to a suspension of (3aRS,7aRS)-2-[(1-ethoxy-2-phenyl)ethylidene]-4-oxo-7,7-diphenyl-perhydroisoindolium tetrafluoborate (2.1 g) in anhydrous dichloromethane (15 cc).
  • the reaction mixture is stirred for 16 hours at 20° C. and then diluted with a 20% aqueous solution (50 cc) of potassium carbonate and dichlormethane (50 cc), stirred and then filtered.
  • Infrared spectrum characteristic bands in cm -1 : 3290, 3100-3000, 3000-2825, 1715, 1655, 1615, 1600, 1580, 1495, 1550, 750, 700.
  • Benzylamine (1.3 cc) is added to a stirred suspension of (3aRS,7aRS)-2-[(1-ethoxy-2-phenyl)ethylidene]-4-oxo-7,7-diphenyl-perhydroisoindolium tetrafluoborate (6.5 g), prepared in accordance with Example 4, in anhydrous dichloromethane (25 cc). Stirring of the reaction mixture is continued for 20 hours at ambient temperature; the reaction mixture is diluted with dichloromethane (30 cc) and treated with an aqueous solution (30 cc) containing potassium carbonate (44 g).
  • Phenethylamine (0.9 cc) is added to a stirred suspension of (3aRS,7aRS)-2-[(1-ethoxy-2-phenyl)ethylidene]-4-oxo-7,7-diphenyl-perhydroisoindolium tetrafluoborate (3.75 g), prepared in accordance with Example 4, in anhydrous dichloromethane (40 cc), which is cooled to +5° C. Stirring of the reaction mixture is continued for 20 hours at ambient temperature; the reaction mixture is treated with a 10% aqueous solution (30 cc) of potassium carbonate.
  • 3-Phenylpropylamine (1.15 cc) is added to a stirred suspension of (3aRS,7aRS)-2-[(1-ethoxy-2-phenyl)ethylidene]-4-oxo-7,7-diphenyl-perhydroisoindolium tetrafluoborate (5.25 g), prepared in accordance with Example 4, in anhydrous dichloromethane (30 cc), which is cooled to +5° C. The temperature of the reaction mixture is then allowed to rise to ambient temperature and stirring is continued for 20 hours. The reaction mixture is treated with a 10% aqueous solution (20 cc) of potassium carbonate.
  • Aminodiphenylmethane (1.7 cc) is added to a stirred suspension of (3aRS,7aRS)-2-[(1-ethoxy-2-phenyl)ethylidene]-4-oxo-7,7-diphenyl-perhydroisoindolium tetrafluoborate (5 g), prepared in accordance with Example 4, in anhydrous dichloromethane (10 cc). Stirring of the reaction mixture is continued for 20 hours at ambient temperature and the reaction mixture is then treated with a saturated aqueous solution (20 cc) of potassium carbonate. The precipitate present is removed by filtration and the organic phase is then dried over magnesium sulphate and concentrated to dryness under reduced pressure (2.7 kPa).
  • 2-Fluorobenzylamine (1 cc) is added to a stirred suspension of (3aRS,7aRS)-2-[(1-ethoxy-2-phenyl)ethylidene]-4-oxo-7,7-diphenyl-perhydroisoindolium tetrafluoborate (4.5 g), prepared in accordance with Example 4, in anhydrous dichloromethane (10 cc). Stirring of the reaction mixture is continued for 20 hours at ambient temperature; the reaction mixture is diluted with dichloromethane (20 cc) and treated with a saturated aqueous solution (20 cc) of potassium carbonate.
  • 3-Fluorobenzylamine (0.95 cc) is added to a stirred suspension of (3aRS,7aRS)-2-[(1-ethoxy-2-phenyl)ethylidene]-4-oxo-7,7-diphenyl-perhydroisoindolium tetrafluoborate (4.2 g), prepared in accordance with Example 4, in anhydrous dichloromethane (10 cc). Stirring of the reaction mixture is continued for 20 hours at ambient temperature; the reaction mixture is diluted with dichloromethane (20 cc) and treated with a saturated aqueous solution (20 cc) of potassium carbonate.
  • 2-Chlorobenzylamine (1.2 cc) is added to a stirred suspension of (3aRS,7aRS)-2-[(1-ethoxy-2-phenyl)ethylidene]-4-oxo-7,7-diphenyl-perhydroisoindolium tetrafluoborate (5 g), prepared in accordance with Example 4, in anhydrous dichloromethane (10 cc). Stirring of the reaction mixture is continued for 20 hours at ambient temperature; the reaction mixture is treated with a saturated aqueous solution (20 cc) of potassium carbonate. The precipitate present is removed by filtration and the organic phase is then dried over magnesium sulphate and concentrated to dryness under reduced pressure (2.7 kPa).
  • 2-Methoxybenzylamine (1 cc) is added to a stirred suspension of (3aRS,7aRS)-2-[(1-ethoxy-2-phenyl)ethylidene]-4-oxo-7,7-diphenyl-perhydroisoindolium tetrafluoborate (4.1 g), prepared in accordance with Example 4, in anhydrous dichloromethane (10 cc). Stirring of the reaction mixture is continued for 20 hours at ambient temperature; the reaction mixture is diluted with dichloromethane (20 cc) and treated with a saturated aqueous solution (20 cc) of potassium carbonate.
  • 3-Methoxybenzylamine (1 cc) is added to a stirred suspension of (3aRS,7aRS)-2-[(1-ethoxy-2-phenyl)ethylidene]-4-oxo-7,7-diphenyl-perhydroisoindolium tetrafluoborate (4.1 g), prepared in accordance with Example 4, in anhydrous dichloromethane (10 cc). Stirring of the reaction mixture is continued for 20 hours at ambient temperature; the reaction mixture is diluted with dichloromethane (20 cc) and treated with a saturated aqueous solution (20 cc) of potassium carbonate.
  • 1-Aminomethylnaphthalene (1.4 cc) is added to a stirred suspension of (3aRS,7aRS)-2-[(1-ethoxy-2-phenyl)ethylidene]-4-oxo-7,7-diphenyl-perhydroisoindolium tetrafluoborate (5 g), prepared in accordance with Example 4, in anhydrous dichloromethane (10 cc). Stirring of the reaction mixture is continued for 20 hours at ambient temperature and the reaction mixture is then treated with a saturated aqueous solution (20 cc) of potassium carbonate. The precipitate present is removed by filtration and the organic phase is then dried over magnesium sulphate and concentrated to dryness under reduced pressure (2.7 kPa).
  • 2-Aminomethylthiophene (1 cc) is added to a stirred suspension of (3aRS,7aRS)-2-[(1-ethoxy-2-phenyl)ethylidene]-4-oxo-7,7-diphenyl-perhydroisoindolium tetrafluoborate (5 g), prepared in accordance with Example 4, in anhydrous dichlormethane (10 cc). Stirring of the reaction mixture is continued for 20 hours at ambient temperature and the reaction mixture is then treated with a saturated aqueous solution (20 cc) of potassium carbonate. The precipitate present is removed by filtration and the organic phase is then dried over magnesium sulphate and concentrated to dryness under reduced pressure (2.7 kPa).
  • Furfurylamine (0.85 cc) is added to a stirred suspension of (3aRS,7aRS)-2-[(1-ethoxy-2-phenyl)ethylidene]-4-oxo-7,7-diphenyl-perhydroisoindolium tetrafluoborate (5 g), prepared in accordance with Example 4, in anhydrous dichloromethane (10 cc). Stirring of the reaction mixture is continued for 20 hours at ambient temperature and the reaction mixture is then treated with a saturated aqueous solution (20 cc) of potassium carbonate. The precipitate present is removed by filtration and the organic phase is then dried over magnesium sulphate and concentrated to dryness under reduced pressure (2.7 kPa).
  • 2-Aminomethylpyridine (0.9 cc) is added to a stirred suspension of (3aRS,7aRS)-2-[(1-ethoxy-2-phenyl)ethylidene]-4-oxo-7,7-diphenyl-perhydroisoindolium tetrafluoborate (4.5 g), prepared in accordance with Example 4, in anhydrous dichloromethane (10 cc). Stirring of the reaction mixture is continued for 20 hours at ambient temperature; the reaction mixture is treated with a saturated aqueous solution (20 cc) of potassium carbonate. The precipitate present is removed by filtration and the organic phase is then dried over magnesium sulphate and concentrated to dryness under reduced pressure (2.7 kPa).
  • 3-Aminomethylpyridine (0.9 cc) is added to a stirred suspension of (3aRS,7aRS)-2-[(1-ethoxy-2-phenyl)ethylidene]-4-oxo-7,7-diphenyl-perhydroisoindolium tetrafluoborate (4.5 g), prepared in accordance with Example 4, in anhydrous dichloromethane (10 cc). Stirring of the reaction mixture is continued for 20 hours at ambient temperature; the reaction mixture is treated with a saturated aqueous solution (20 cc) of potassium carbonate. The precipitate present is removed by filtration and the organic phase is then dried over magnesium sulphate and concentrated to dryness under reduced pressure (2.7 kPa).
  • N,N-Dimethylhydrazine (0.53 cc) is added to a stirred suspension of (3aRS,7aRS)-2-[(1-ethoxy-2-phenyl)ethylidene]-4-oxo-7,7-diphenyl-perhydroisoindolium tetrafluoborate (3.75 g), prepared in accordance with Example 4, in anhydrous dichloromethane (40 cc), cooled to +5° C. The reaction mixture is stirred for 1 hour at +5° C. and then for 20 hours at ambient temperature; it is treated with a saturated aqueous solution (30 cc) of potassium carbonate.
  • the precipitate present is removed by filtration and the organic phase is then washed with distilled water (30 cc), dried over magnesium sulphate and concentrated to dryness under reduced pressure (2.7 kPa).
  • the residue is chromatographed on a Pechiney CBT1 neutral alumina gel column (diameter 3 cm, height 30 cm), eluting with a mixture of cyclohexane and ethyl acetate (50/50 by volume) and collecting 60 cc fractions.
  • Fraction 2 is concentrated to dryness under reduced pressure (2.7 kPa).
  • the residue is recrystallized from acetonitrile (10 cc); the crystals obtained are drained.
  • N,N'-Carbonyldiimidazole (1.14 g) is added to a solution of 2-fluorophenylacetic acid (1.08 g) in dry dichloromethane (30 cc) cooled to +5° C. The mixture is stirred for 20 minutes at +5° C. and a solution of (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (2.3 g) and triethylamine (1.98 cc) in dichloromethane (20 cc) is then added. The reaction mixture is stirred at 20° C.
  • N,N'-Carbonyldiimidazole (1.13 g) is added to a solution of 2-(4-fluorophenyl)acetic acid (1.08 g) in dry dichloromethane (30 cc), cooled to +5° C. The mixture is stirred for 1 hour at +5° C. and a solution of 7,7-diphenyl-4-perhydroisoindolone hydrochloride (2.3 g) and triethylamine (0.98 cc) in dichloromethane (40 cc) is then added. The reaction mixture is stirred for 1 hour at +5° C. and then for 16 hours at 20° C.
  • N,N'-Carbonyldiimidazole (1.13 g) is added to a solution of 2-(2,6-difluorophenyl)acetic acid (1.2 g) in dry dichloromethane (30 cc), cooled to +5° C. The mixture is stirred for 45 minutes at +5° C. and a solution of (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (2.3 g) and triethylamine (0.98 cc) in dichloromethane (40 cc) is then added. The reaction mixture is stirred at 20° C.
  • N,N'-Carbonyldiimidazole (1.13 g) is added to a solution of 2-chlorophenylacetic acid (1.19 g) in dry dichloromethane (30 cc), cooled to +5° C. The mixture is stirred for 15 minutes at +5° C. and a solution of (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (2.28 g) and triethylamine (1.96 cc) in dichloromethane (20 cc) is then added. The reaction mixture is stirred at 20° C.
  • N,N'-Carbonyldiimidazole (1.13 g) is added to a solution of 3-chlorophenylacetic acid (1.19 g) in dry dichloromethane (30 cc), cooled to +5° C. The mixture is stirred for 15 minutes at +5° C. and a solution of (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (2.28 g) and triethylamine (1.96 cc) in dichloromethane (20 cc) is then added. The reaction mixture is stirred at 20° C.
  • N,N'-Carbonyldiimidazole (1.3 g) is added to a solution of 2-(4-chlorophenyl)acetic acid (1.36 g) in dry dichloromethane (30 cc), cooled to +5° C. The mixture is stirred for 1 hour at +5° C. and a solution of (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (2.62 g) and triethylamine (1.12 cc) in dichloromethane (20 cc) is then added. The reaction mixture is stirred for 2 hours at +5° C.
  • N,N'-Carbonyldiimidazole (1.13 g) is added to a solution of 2-(2,6-dichlorophenyl)acetic acid (1.43 g) in dry dichloromethane (30 cc), cooled to +5° C. The mixture is stirred for 30 minutes at +5° C. and a solution of (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (2.3 g) and triethylamine (0.98 cc) in dichloromethane (40 cc) is then added. The reaction mixture is stirred at 20° C.
  • N,N'-Carbonyldimidazole (1.13 g) is added to a solution of 2-(2-bromophenyl)acetic acid (1.5 g) in dry dichloromethane (30 cc), cooled to +5° C. The mixture is stirred for 45 minutes at +5° C. and a solution of (3aRS,7aRS)-7,7-diphenyl-4-perhydroiso-indolone hydrochloride (2.3 g) and triethylamine (0.98 cc) in dichloromethane (40 cc) is then added. The reaction mixture is stirred for 4 hours at 20° C.
  • N,N'-Carbonyldiimidazole (1.14 g) is added to a solution of 2-hydroxyphenylacetic acid (1.06 g) in dry dichloromethane (30 cc), cooled to +5° C. The mixture is stirred for 30 minutes at +5° C. and a solution of (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (2.23 g) and triethylamine (1.96 cc) in dichloromethane (20 cc) is then added. The reaction mixture is stirred at 20° C.
  • N,N'-Carbonyldiimidazole (1.13 g) is added to a solution of 2-(2-methylphenyl)acetic acid (1.05 g) in dry dichloromethane (30 cc), cooled to +5° C. The mixture is stirred for 40 minutes at +5° C. and a solution of (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (2.3 g) and triethylamine (0.98 cc) in dichloromethane (20 cc) is then added. The reaction mixture is stirred at 20° C.
  • N,N'-Carbonyldiimidazole (1.13 g) is added to a solution of 2-(3-methylphenyl)acetic acid (1.05 g) in dry dichloromethane (30 cc), cooled to +5° C. The mixture is stirred for 35 minutes at +5° C. and a solution of (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (2.3 g) and triethylamine (0.98 cc) in dichloromethane (20 cc) is then added. The reaction mixture is stirred at 20° C.
  • N,N'-Carbonyldiimidazole (1.13 g) is added to a solution of 3-(trifluoromethyl)phenylacetic acid (1.43 g) in dry dichloromethane (30 cc), cooled to +5° C. The mixture is stirred for 15 minutes at +5° C. and a solution of (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (2.28 g) and triethylamine (1.96 cc) in dichloromethane (20 cc) is then added. The reaction mixture is stirred at 20° C.
  • N,N'-Carbonyldiimidazole (1.13 g) is added to a solution of 2-(2-(trifluoromethyl)phenyl)acetic acid (1.42 g) in dry dichloromethane (30 cc), cooled to +5° C. The mixture is stirred for 1 hour 45 minutes at +5° C. and a solution of (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (2.3 g) and triethylamine (0.98 cc) in dichloromethane (40 cc) is then added. The reaction mixture is stirred at 20° C.
  • N,N'-Carbonyldiimidazole (0.37 g) is added to a solution of 2-(tert-butoxycarbonylaminomethyl)phenylacetic acid (0.6 g) in dry dichloromethane (20 cc), cooled to +5° C. The mixture is stirred for 30 minutes at +5° C. and a solution of (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (0.75 g) and triethylamine (0.6 cc) in dichloromethane (20 cc) is then added. The reaction mixture is stirred at 20° C.
  • Proton NMR spectrum At ambient temperature, the mixture of the two rotamers is observed: 2 to 2.35 (Mt, 2H, --CH 2 -- in 5 or 6); 2.65 to 3.15 (Mt, 4H, --CH 2 -- in 1 and --CH 2 -- in 6 or 5); 3.20 to 4.5 (Mt, --CH 2 -- in 3, --CH-- in 3a, --CH-- in 7, --N--CO--CH 2 -- and --CH 2 N--); 7.05 to 7.7 (Mt, 14H, aromatic).
  • Infrared spectrum (KBr), characteristic bands (cm -1 ): 3600-3250, 3100-3000, 3000-2800, 2750-2250, 1715, 1620, 1600, 1580, 1495, 1475, 1445, 1440, 755, 703.
  • 2-(tert-Butoxycarbonylaminomethyl)phenyl acetic acid is prepared by the method described in Japanese Patent Application 74 24 975.
  • N,N'-Carbonyldiimidazole (1.13 g) is added to a solution of 2-methoxyphenylacetic acid (1.16 g) in dry dichloromethane (30 cc), cooled to +5° C. The mixture is stirred for 15 minutes at +5° C. and a solution of (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (2.28 g) and triethylamine (1.96 cc) in dichloromethane (20 cc) is then added. The reaction mixture is stirred at 20° C.
  • Triethyloxonium tetrafluoborate (2.35 g) is added to a solution of (3aRS,7aRS)-7,7-diphenyl-2-[(2-methoxyphenyl)acetyl]-4-perhydroisoindolone (5 g) in dichloromethane (10 cc). Stirring of the reaction mixture is continued for 20 hours at ambient temperature; the reaction mixture is then treated with ether (100 cc) and the precipitate obtained is drained, washed with ether (100 cc) and dried.
  • a 5.4N ethanolic ammonia solution (1.3 cc) is added to a stirred suspension of (3aRS,7aRS)-2-[(1-ethoxy-2-(2-methoxyphenyl))ethylidene]-4-oxo-7,7-diphenyl-perhydroisoindolium tetrafluoborate (5.7 g) in anhydrous dichloromethane (15 cc), which is cooled to to -10° C. The temperature of the reaction mixture is then allowed to rise to ambient temperature and stirring is continued for 20 hours. The reaction mixture is diluted with dichloromethane (20 cc) and treated with a 10% aqueous solution (20 cc) of potassium carbonate.
  • N,N'-Carbonyldiimidazole (1 g) is added to a solution of 2-methoxyphenylacetic acid (1 g) in dry dichloromethane (30 cc), cooled to +5° C. The mixture is stirred for 40 minutes at +5° C. and a solution of (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (2 g) and triethylamine (1.7 cc) in dichloromethane (40 cc) is then added. The reaction mixture is stirred at 20° C.
  • Triethyloxonium tetrafluoborate (4 g) is added to a solution of (3aR,7aR)-7,7-diphenyl-2-[(2-methoxyphenyl)acetyl]-4-perhydroisoindolone (7.7 g) in anhydrous dichloromethane (13 cc). Stirring of the reaction mixture is continued for 20 hours at ambient temperature; the mixture is then cooled to -15° C. and a 5.4N ethanolic ammonia solution (2.6 cc) is then added. The temperature of the reaction mixture is allowed to rise to ambient temperature and stirring is continued for 5 hours and a half.
  • the reaction mixture is treated with a 10% aqueous solution (20 cc) of potassium carbonate; the precipitate formed is drained and washed with dichloromethane (10 cc).
  • the organic phases are combined, dried over magnesium sulphate and concentrated to dryness under reduced pressure (2.7 kPa).
  • the residue is crystallized from acetonitrile (10 cc); the crystals obtained are drained, washed with acetonitrile (5 cc) and with isopropyl ether (10 cc) and dried.
  • N,N'-Carbonyldiimidazole (1.13 g) is added to a solution of 2-methoxyphenylacetic acid (1.16 g) in dry dichloromethane (30 cc), cooled to +5° C. The mixture is stirred for 15 minutes at +5° C. and a solution of (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (2.28 g) and triethylamine (1.96 cc) in dichloromethane (20 cc) is then added. The reaction mixture is stirred at 20° C.
  • N,N'-Carbonyldiimidazole (0.52 g) is added to a solution of 2-(2,6-dimethoxyphenyl)acetic acid (0.63 g) in dry dichloromethane (20 cc), cooled to +5° C. The mixture is stirred for 35 minutes at +5° C. The mixture is stirred for 35 minutes at +5° C. and a solution of (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (1.05 g) and triethylamine (0.44 cc) in dichloromethane (25 cc) is then added. The reaction mixture is stirred at 20° C.
  • 2-(2,6-Dimethoxyphenyl)acetic acid can be prepared in the following way:
  • a mixture of N-[2-(2,6-dimethoxyphenyl)thioacetyl]morpholine and a 10% aqueous potassium hydroxide solution (40 cc) is refluxed for 12 hours.
  • the reaction mixture is extracted with ethyl acetate (100 cc); the organic phase is acidified by addition of 4N hydrochloric acid (25 cc).
  • the aqueous phase is extracted with ethyl acetate (2 ⁇ 100 cc).
  • the organic phases are combined and washed with distilled water (3 ⁇ 100 cc), dried over magnesium sulphate and filtered and the filtrate is concentrated to dryness under reduced pressure (2.7 kPa).
  • N-[2-(2,6-Dimethoxyphenyl)thioacetyl]-morpholine can be prepared in the following way:
  • N,N'-Carbonyldiimidazole (1.14 g) is added to a solution of 2,5-dimethoxyphenylacetic acid (1.34 g) in dry dichloromethane (30 cc), cooled to +5° C. The mixture is stirred for 30 minutes at +5° C. and a solution of (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (2.28 g) and triethylamine (1.96 cc) in dichloromethane (20 cc) is then added. The reaction mixture is stirred at 20° C.
  • N,N'-Carbonyldiimidazole (0.77 g) is added to a solution of 2-methylthiophenylacetic acid (0.87 g) in dry dichloromethane (30 cc), cooled to +5° C. The mixture is stirred for 15 minutes at +5° C. and a solution of (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (1.56 g) and triethylamine (1.34 cc) in dichloromethane (30 cc) is then added. The reaction mixture is stirred at 20° C.
  • 2-Methylthiophenylacetic acid is prepared by the method of G. Kompa et St. Weckmann (J. Prak. Chem. [2], 138, 123 (1933)).
  • N,N'-Carbonyldiimidazole (1.62 g) is added to a solution of (2-tert-butoxycarbonylaminophenyl)acetic acid (2.51 g) in dry dichloromethane (30 cc), cooled to +5° C. The mixture is stirred for 45 minutes at +5° C. and a solution of (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (3.27 g) and triethylamine (2.8 cc) in dichloromethane (30 cc) is then added. The reaction mixture is stirred at 20° C.
  • a solution of (2-nitrophenyl)acetic acid (18.1 g) in normal sodium hydroxide solution (120 cc) is hydrogenated in an autoclave under a pressure of 5 bar for 2.5 hours at 20° C. in the presence of 3% palladium-on-carbon black (1.5 g).
  • the solution of sodium (2-aminophenyl)acetate thus obtained is cooled to +5° C. and then treated with a solution of di-tert-butyl dicarbonate (26.16 g) in tetrahydrofuran (100 cc) and then with normal sodium hydroxide solution (80 cc).
  • the reaction mixture is stirred at 20° C.
  • N,N'-Carbonyldiimidazole (1.13 g) is added to a solution of (N-tert-butoxycarbonyl-2-N-methylamino-phenyl)acetic acid (1.85 g) in dry dichloromethane (30 cc), cooled to +5° C. The mixture is stirred for 30 minutes at +5° C. and a solution of (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (2.29 g) and triethylamine (1.9 cc) in dichloromethane (20 cc) is then added. The reaction mixture is stirred at 20° C.
  • a solution of methyl (N-tert-butoxycarbonyl-2-N-methylamino-phenyl)acetate (3.5 g) in ethanol (50 cc) is treated with normal sodium hydroxide solution (15 cc) at 80° C. for 4 hours.
  • the reaction mixture is concentrated under reduced pressure (2.7 kPa).
  • the residue is taken up in water (100 cc) and the solution, acidified to pH 1 by the action of 4N hydrochloric acid, is extracted with ethyl acetate (2 ⁇ 100 cc).
  • Methyl (N-tert-butoxycarbonyl-2-N-methylamino-phenyl)acetate can be prepared in the following way:
  • N,N'-Carbonyldiimidazole (0.81 g) is added to a solution of (N-tert-butoxycarbonyl-2-N-ethylaminophenyl)acetic acid (1.4 g) in dry dichloromethane (30 cc), cooled to +5° C. The mixture is stirred for 30 minutes at +5° C. and a solution of (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (1.63 g) and triethylamine (1.4 cc) in dichloromethane (20 cc) is then added. The reaction mixture is stirred at 20° C.
  • Infrared spectrum (KBr), characteristic bands (cm -1 ): 3600-3300, 3465, 3105-3000, 3000-2870, 1715, 1625, 1595, 1525, 1495, 1475, 1445, 1410, 755, 705.
  • Ethyl (N-tert-butoxycarbonyl-2-N-ethylaminophenyl)acetate can be prepared in the following way:
  • N,N'-Carbonyldiimidazole (0.5 g) is added to a solution of (N-tert-butoxycarbonyl-2-N-propylaminophenyl)acetic acid (0.9 g) in dry dichloromethane (25 cc), cooled to +5° C. The mixture is stirred at +5° C. for 30 minutes and a solution of (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (1 g) and triethylamine (0.87 cc) in dichloromethane (15 cc) is then added. The reaction mixture is stirred at 20° C.
  • Propyl (N-tert-butoxycarbonyl-2-N-propylamino-phenyl)acetate can be prepared in the following way:
  • N,N'-Carbonyldiimidazole (1 g) is added to a solution of 2-dimethylaminophenylacetic acid (1.1 g) in dry dichloromethane (30 cc), cooled to +5° C. The mixture is stirred at +5° C. for 30 minutes and a solution of (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (2.03 g) and triethylamine (1.68 cc) in dichloromethane (20 cc) is then added. The reaction mixture is stirred at 20° C.
  • 2-Dimethylaminophenylacetic acid is prepared by the method of D-U. Lee, K. K. Mayer and W. Wiegrebe (Arch. Pharm. (Weinheim), 321, 303 (1988)).
  • N,N'-Carbonyldiimidazole (2.43 g) is added to a solution of 2-dimethylaminophenylacetic acid (2.68 g) in dry dichloromethane (50 cc), cooled to +5° C. The mixture is stirred at +5° C. for 90 minutes and a solution of (3aR,7aR)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (4.9 g) and triethylamine (4.2 cc) in dichloromethane (50 cc) is then added. The reaction mixture is stirred at 20° C.
  • N,N'-Carbonyldiimidazole (0.86 g) is added to a solution of 2-diethylaminophenylacetic acid (1.1 g) in dry dichloromethane (30 cc), cooled to +5° C. The mixture is stirred at +5° C. for 30 minutes and a solution of (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (1.73 g) and triethylamine (1.48 cc) in dichloromethane (40 cc) is then added. The reaction mixture is stirred at 20° C.
  • 2-Diethylaminonphenylacetic acid is prepared by hydrogenation of a suspension of 2-nitrophenylacetic acid (9 g) in ethanol (40 cc) under a pressure of 7 bar for 4 hours at 25° C. in the presence of acetaldehyde (7 cc) and 10% palladium-on-carbon black (1 g).
  • reaction mixture is filtered, the filtrate is concentrated to dryness under reduced pressssure (2.7 kPa) and the residue is chromatographed on a silica column (0.2-0.063 mm, diameter 5 cm, height 50 cm), eluting under a nitrogen pressure of 0.7 bar with a mixture of cyclohexane and ethyl acetate (70/30 by volume) and collecting 125 cc fractions.
  • Fractions 38 to 48 are concentrated to dryness under reduced pressure (2.7 kPa) to give 2-diethylaminophenylacetic acid (1.1 g) in the form of a yellow oil.
  • N,N'-Carbonyldiimidazole (1.62 g) is added to a solution of (2-dimethylamino-6-fluorophenyl)acetic acid (1.97 g) in dry dichloromethane (50 cc), cooled to +5° C. The mixture is stirred for 90 minutes at +5° C. and a solution of (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (3.27 g) and triethylamine (2.8 cc) in dichloromethane (50 cc) is then added. The reaction mixture is stirred at 20° C.
  • N,N'-Carbonyldiimidazole (1.64 g) is added to a solution of (2-dimethylamino-4-fluorophenyl)acetic acid (2 g) in dry dichloromethane (50 cc), cooled to +5° C. The mixture is stirred for 90 minutes at +5° C. and a solution of (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (3.3 g) and triethylamine (2.8 g) in dichloromethane (50 cc) is then added. The reaction mixture is stirred at 20° C.
  • (2-Dimethylamino-4-fluorophenyl)acetic acid is prepared in the following way: 10% palladium-on-charcoal (0.6 g) is added to a solution of (4-fluoro-2-nitrophenyl)acetic acid (5.5 g) and 37% aqueous formaldehyde solution (15 cc) in ethanol (130 cc), in a 250 cm 3 autoclave, and the autoclave is then placed under a hydrogen pressure of 47 bar and the mixture is stirred at ambient temperature for 48 hours. The reaction mixture is then filtered and the filtrate is concentrated to dryness under reduced pressure (2.7 kPa).
  • N,N'-Carbonyldiimidazole (1.13 g) is added to a solution of 2-[2-(1-pyrrolydinyl)phenyl]acetic acid (1.42 g) in dry dichloromethane (30 cc), cooled to +5° C. The mixture is stirred for 40 minutes at +5° C. and a solution of (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (2.3 g) and triethylamine (0.98 cc) in dichloromethane (20 cc) is then added. The reaction mixture is stirred for 1 hour at +5° C. and then for 1 hour at 20° C.
  • N,N'-Carbonyldiimidazole (0.35 g) is added to a solution of 2-[2-(4-morpholinyl)phenyl]acetic acid (0.48 g) in dry dichloromethane (25 cc), cooled to +5° C. The mixture is stirred for 75 minutes at +5° C. and a solution of (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (0.71 g) and triethylamine (0.6 cc) in dichloromethane (20 cc) is then added. The reaction mixture is stirred for 1 hour at +5° C. and then for 8 hours at 20° C.
  • 2-[2-(4-Morpholinyl)phenyl]acetic acid can be prepared in the following way:
  • N-[[2-(4-Morpholinyl)phenyl]thioacetyl]morpholine can be prepared in the following way:
  • 2-(4-Morpholino)acetophenone can be prepared in the following way:
  • a mixture of 2-fluoroacetophenone (19.9 g), morpholine (21 cc) and potassium carbonate (27.6 g) in dimethyl sulphoxide (32 cc) is heated at 110° C. for 30 hours.
  • the reaction mixture is diluted with water (100 cc) and extracted with ethyl acetate (4 ⁇ 100 cc); the organic solution is washed with distilled water (100 cc), dried over magnesium sulphate and concentrated to dryness under reduced pressure (2.7 kPa).
  • N,N'-Carbonyldiimidazole (1.13 g) is added to a solution of 2-(1-naphthyl)acetic acid (1.3 g) in dry dichloromethane (30 cc), cooled to +5° C. The mixture is stirred for 25 minutes at +5° C. and a solution of (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (2.3 g) and triethylamine (0.98 cc) in dichloromethane (40 cc) is then added. The reaction mixture is stirred at 20° C.
  • N,N'-Carbonyldiimidazole (0.81 g) is added to a solution of 2-(2-thienyl)acetic acid (0.71 g) in dry dichloromethane (20 cc), cooled to +5° C. The mixture is stirred for 1 hour at +5° C. and a solution of 7,7-diphenyl-4-perhydroisoindolone hydrochloride (1.6 g) and triethylamine (0.7 cc) in dichloromethane (20 cc) is then added. The reaction mixture is stirred for 2 hours at +5° C. and for 16 hours at 20° C.
  • N,N'-Carbonyldiimidazole (1.13 g) is added to a solution of 2-(3-thienyl)acetic acid (0.99 g) in dry dichloromethane (30 cc), cooled to +5° C. The mixture is stirred for 15 minutes at +5° C. and a solution of (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (2.24 g) and triethylamine (1.96 cc) in dichloromethane (20 cc) is then added.
  • N,N'-Carbonyldiimidazole (1.13 g) is added to a solution of 2-(1,3-dithiin-5-yl)acetic acid (1.23 g) in dry dichloromethane (30 cc), cooled to +5° C. The mixture is stirred for 20 minutes at +5° C. and a solution of (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (2.3 g) and triethylamine (0.98 cc) in dichloromethane (40 cc) is then added. The reaction mixture is stirred for 16 hours at 20° C.
  • Triethylamine (1.4 cc) is added to a suspension of 2-(2-pyridyl)acetic acid hydrochloride (1.73 g) in dry dichloromethane (30 cc). The solution is cooled to +5° C. and then treated with N,N'-carbonyldiimidazole (1.62 g). The mixture is stirred for 15 minutes at +5° C. and a solution of (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (3.27 g) and triethylamine (2.8 cc) in dichloromethane (20 cc) is then added. The reaction mixture is stirred at 20° C.
  • N,N'-Carbonyldiimidazole (0.81 g) is added to a solution of 2-(3-pyridyl)acetic acid (0.685 g) in dry dichloromethane (15 cc), cooled to +5° C. The mixture is stirred for 30 minutes at +5° C. and a solution of (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (1.6 g) and triethylamine (0.7 cc) in dichloromethane (10 cc) is then added. The reaction mixture is stirred at 20° C. for 16 hours and then concentrated to dryness under reduced pressure (2.7 kPa).
  • the crystals obtained are recrystallized from acetonitrile (cc) to give (3aRS,7aRS)-7,7-diphenyl-2-[2-(3-pyridyl)acetyl]-4-perhydroisoindolone (0.9 g) in the form of white crystals melting at 208° C.
  • N,N'-Carbonyldiimidazole (4.05 g) is added to a solution of 2-(3-indolyl)acetic acid (4.37 g) in dry dichloromethane (100 cc), cooled to +5° C. The mixture is stirred for 1 hour at +5° C. and (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone (7.3 g) is then added. The reaction mixture is stirred at 20° C. for 20 hours, then washed with distilled water (3 ⁇ 50 cc), dried over magnesium sulphate and filtered and the filtrate is concentrated to dryness under reduced pressure (2.7 kPa).
  • the residue is chromatographed on a silica gel column (0.2-0.063 mm, diameter 7 cm, height 40 cm), eluting with a mixture of ethyl acetate and cyclohexane (70/30 by volume) and collecting 100 cc fractions. Fractions 6 to 11 are concentrated to dryness under reduced pressure (2.7 kPa). The residue is recrystallized from acetonitrile (50 cc). The crystals obtained are drained, washed with isopropyl ether (10 cc) and dried. (3aRS,7aRS)-7,7-diphenyl-2-[2-(3-indolyl)acetyl]-4-perhydroisoindolone (5 g) melting at 250° C. is obtained.
  • Infrared spectrum characteristic bands in cm -1 : 3100-3000, 3000-2875, 1715, 1655, 1600, 1580, 1495, 1450, 750, 700.
  • N,N'-Carbonyldiimidazole (0.66 g) is added to a solution of (S)-2-phenylpropionic acid (0.62 g) in dry dichloromethane (30 cc), cooled to +5° C. The mixture is stirred for 40 minutes at +5° C. and a solution of (3aR,7aR)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (1.35 g) and triethylamine (0.57 cc) in dichloromethane (40 cc) is then added. The reaction mixture is stirred at 20° C.
  • Infrared spectrum (KBr), characteristic bands (cm -1 ): 3600-3300, 3100-3000, 3000-2870, 1715, 1640, 1600, 1580, 1495, 1455, 1445, 1420, 1370, 755, 700.
  • N,N'-Carbonyldiimidazole (0.66 g) is added to a solution of (R)-2-phenylpropionic acid (0.62 g) in dry dichloromethane (30 cc), cooled to +5° C. The mixture is stirred for 30 minutes at +5° C. and a solution of (3aR,7aR)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (1.35 g) and triethylamine (0.57 cc) in dichloromethane (40 cc) is then added. The reaction mixture is stirred at 20° C. for 16 hours and then concentrated to dryness under reduced pressure (2.7 kPa).
  • the residue is dissolved in ethyl acetate (100 cc) and the solution is washed with water (2 ⁇ 50 cc), dried over magnesium sulphate and filtered and the filtrate is concentrated to dryness under reduced pressure (4 kPa).
  • the residue is chromatographed on a silica gel column (0.2-0.04 mm, diameter 2.8 cm, height 15 cm), eluting under a nitrogen pressure of 0.5 bar with a mixture of cyclohexane and ethyl acetate (60/40 by volume) and collecting 50 cc fractions.
  • Proton NMR spectrum 1.2 and 1.28 (2D, 3H in total, --CH 3 ); 1.9 to 2.3 (Mt, 2H, --CH 2 -- in 5 or 6); 2.50 to 3.15 (Mt, 4H, --CH 2 -- in 6 or 5 and --CH 2 -- in 1); 3.15 to 4.05 (Mt, --CH-- in 3a, 1H of the --CH 2 -- in 3, --N--CO--CH--, --CH-- in 7a); 4 to 4.21 (Mt, 1H of the --CH 2 -- in 3); 6.85 to 7.7 (Mt, 15H, aromatic).
  • N,N'-Dicyclohexylcarbodiimide (0.91 g) is added, the mixture is stirred for 1 hour at this temperature and a solution of (3aR,7aR)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (1.44 g) and N,N-diisopropylethylamine (0.76 cc) in dimethylformamide (10 cc) is then added. The reaction mixture is stirred at 20° C. for 16 hours, diluted with ethyl acetate (100 cc) and concentrated to dryness under reduced pressure (2.7 kPa) after filtering off the precipitate.
  • the residue is chromatographed on a silica gel column (0.2-0.063 mm, diameter 3 cm, height 40 cm), eluting under a nitrogen pressure of 0.7 bar with a mixture of cyclohexane and ethyl acetate (50/50 by volume) and collecting 125 cc fractions. Fractions 4 to 7 are combined and concentrated to dryness under reduced pressure (2.7 kPa). The residue is purified by dissolving in boiling isopropyl ether (60 cc) to which hexane (30 cc) had been added.
  • Proton NMR spectrum At ambient temperature the mixture of the two rotamers of each of the two diastereoisomers is observed, the two diastereoisomers being in the proportions 90/10. 1.10 and 1.20 (2 Mt, 3H in total, --CH 3 ); 1.9 to 2.4 (Mt, 2H, --CH 2 -- in 5 or 6); 2.55 to 2.95 (Mt, --CH 2 -- in 1 and --CH 2 -- in 6 or 5); 2.95 to 3.4 (Mt, 1H of the --CH 2 -- in 3 and --CH-- in 3a); 3.20-3.32-3.50 and 3.83 (4S, --OCH 3 ); 3.65 to 4.3 (Mt, --CH-- in 7a, --N--CO--CH--, 1H of the --CH 2 -- in 3); 6.7 to 7.65 (Mt, 14H, aromatic).
  • Infrared spectrum (KBr), characteristic bands (cm -1 ): 3430, 3100-3000, 3000-2800, 1715, 1640, 1595, 1585, 1490, 1460, 1445, 1420, 1365, 1240, 1030, 755, 703.
  • N,N'-Carbonyldiimidazole (0.85 g) is added to a solution of (RS)-2-[2-dimethylaminophenyl]propionic acid (1 g) in dichloromethane (30 cc) cooled to 5° C. and the mixture is then stirred for 30 minutes at this temperature.
  • a solution of (3aR,7aR)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (1.7 g) and triethylamine (1.4 cc) in dichloromethane (30 cc) is added. The reaction mixture is stirred at 20° C.
  • Proton NMR spectrum At ordinary temperature, the mixture of the two rotamers of each of the two diastereoisomers is observed. 1.15 to 1.35 (Mt, 3H, --CH 3 ); 1.9 to 2.4 (Mt, --CH 2 -- in 5 or 6); 2.1-2.19-2.62-2.64 (45, --N(CH 3 ) 2 ); 2.55 to 3.4 (Mt, --CH 2 -- in 6 or 5, --CH 2 -- in 1, --CH-- in 3a and 1H of the --CH 2 -- in 3); 3.5 to 4.5 (Mt, --N--CO--CH--, 1H of the --CH 2 -- in 3 and --CH in 7a); 7 to 7.7 (Mt, 15H, aromatic).
  • Infrared spectrum (KBr), characteristic bands (cm -1 ): 3600-3300, 3100-3000, 3000-2780, 1715, 1640, 1595, 1580, 1490, 1460, 1445, 1410, 750, 702.
  • the mixture is cooled and diluted with water (20 cc) and ethyl acetate (100 cc).
  • the aqueous phase is washed with ethyl acetate (100 cc), acidified to pH 5 with hydrochloric acid and extracted with ethyl acetate (2 ⁇ 100 cc).
  • the organic phases are washed with water, dried over magnesium sulphate and concentrated to dryness under reduced pressure (2.7 kPa) to give (RS)-2-[2-dimethylaminophenyl]propionic acid in the form of a yellow oil.
  • N,N'-Carbonyldiimidazole (0.49 g) is added to a solution of (S)-2-phenylbutyric acid (0.5 g) in dry dichloromethane (15 cc), cooled to +5° C. The mixture is stirred for 30 minutes at +5° C. and a solution of (3aR,7aR)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (0.98 g) and triethylamine (0.42 cc) in dichloromethane (20 cc) is then added. The reaction mixture is stirred at 20° C.
  • Proton NMR spectrum At ambient temperature, the mixture of the two rotamers is observed. 0.65 and 0.77 (2T, 3H in total, --CH 3 ethyl); 1.4 to 2 (Mt, --CH 2 -- of ethyl); 1.9 to 2.3 (Mt, 2H, --CH 2 -- in 5 or 6); 2.8 (Mt, 4H, --CH 2 -- in 6 or 5 and --CH 2 -- in 1); 3.05 to 3.35 and 3.48 (Mt, --CH-- in 3a, --N--CO--CH-- and 1H of the --CH 2 -- in 3); 3.75 to 4.1, (Mt, 1H, --CH-- in 7a); 4.2 to 4.45 (Mt, 1H, 1H of the --CH 2 -- in 3); 6.9 to 7.65 (Mt, 15H, aromatic).
  • Infrared spectrum (KBr), characteristic bands (cm -1 ): 3600-3300, 3100-3000, 3000-2830, 1715, 1640, 1600, 1580, 1492, 1450, 1445, 1420, 1375, 755 and 700.
  • N,N'-Carbonyldiimidazole (0.5 g) is added to a solution of (S)-3-tert-butoxycarbonylamino-2-phenylpropionic acid (0.79 g) in dry dichloromethane (20 cc), cooled to +5° C. The mixture is stirred for 1 hour 15 minutes at +5° C. and a solution of (3aR,7aR)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (1 g) and triethylamine (0.4 cc) in dichloromethane (25 cc) is then added. The reaction mixture is stirred for 15 minutes at +5° C. and then for 16 hours at 20° C.
  • reaction mixture is washed with distilled water (3 ⁇ 100 cc), dried over magnesium sulphate and filtered and the filtrate is concentrated to dryness under reduced pressure (2.7 kPa).
  • the residue is chromatographed on a silica gel column (0.2-0.06 mm, diameter 3 cm, height 30 cm), eluting with a mixture of cyclohexane and ethyl acetate (50/50 by volume) and collecting 50 cc fractions. Fractions 2 to 7 are combined and concentrated to dryness under reduced pressure (2.7 kPa).
  • (S)-3-Amino-2-phenylpropionic acid can be prepared by a method described by J. A. Carbarino in J. Chem. Soc. Perkin 1, 906 (1981).
  • Hydroxybenzotriazole monohydrate (1 g) is added to a solution of (S)- ⁇ -methoxyphenylacetic acid (1.23 g) in dry dimethylformamide (20 cc), cooled to +5° C.; stirring is continued for 15 minutes and N,N'-dicyclohexylcarbodiimide (1.53 g) is then added. The mixture is stirred for 1 hour at +5° C. and a solution of (3aR,7aR)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (2.43 g) and diisopropylethylamine (1.28 cc) in dry dimethylformamide (10 cc) is then added.
  • reaction mixture is stirred at +5° C. for 2 hours and then at ambient temperature for 2 hours.
  • the reaction mixture taken up in ethyl acetate (100 cc), is filtered; the filtrate is washed with distilled water (2 ⁇ 100 cc), dried over magnesium sulphate and filtered and the filtrate is concentrated to dryness under reduced pressure (2.7 kPa).
  • the residue is chromatographed on a silica gel column (diameter 2.2 cm, height 27 cm), eluting with a mixture of cyclohexane and ethyl acetate (80/20 by volume) and collecting 20 cc fractions. Fractions 68 to 177 are combined and concentrated to dryness under reduced pressure (2.7 kPa).
  • N,N'-Carbonyldiimidazole (1.3 g) is added to a solution of (S)-(+)-O-acetylmandelic acid (1.55 g) in dry dichloromethane (60 cc), cooled to +5° C. The mixture is stirred for 90 minutes at +5° C. and a solution of (3aR,7aR)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (2.6 g) and triethylamine (1.12 cc) in dichloromethane (80 cc) is then added. The reaction mixture is stirred at 20° C. for 16 hours and concentrated to dryness under reduced pressure (2.7 kPa).
  • the residue is taken up in a mixture of ethyl acetate (150 cc) and water (100 cc) and the organic phase is washed with water (50 cc) and then with saturated sodium chloride solution (50 cc), dried over magnesium sulphate and filtered and the filtrate is concentrated to dryness under reduced pressure (2.7 kPa).
  • the residue is chromatographed on a silica gel column (0.4-0.063 mm, diameter 4 cm, height 23 cm), eluting under a nitrogen pressure of 0.5 bar with a mixture of cyclohexane and ethyl acetate (50/50 by volume) and collecting 60 cc fractions.
  • Infrared spectrum (KBr), characteristic bands (cm -1 ): 3090-3065, 2980-2880, 1735, 1720, 1660, 1600, 1585, 1495, 1460, 1445, 1435, 1375, 1240, 700.
  • Infrared spectrum (KBr), characteristic bands (cm -1 ); 3410, 3100-3000, 3000-2870, 1715, 1640, 1600, 1580, 1492, 1460, 1445, 1380, 1065, 755 and 700.
  • (3aR,7aR)-2-[(S)-2-acetoxy-2-phenylacetyl]-7,7-diphenyl-4-perhydroisoindolone can be prepared as described above in Example 81.
  • N,N'-Carbonyldiimidazole (24.3 g) is added to a solution of monobenzyl phenylmalonate (40.5 g) in dry dichloromethane (810 cc), cooled to +5° C. The mixture is stirred for 25 minutes at +5° C. and a solution of (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (49.1 g) and triethylamine (21 cc) in dichloromethane (1,000 cc) is then added. The reaction mixture is stirred at 20° C.
  • the residue is crystallized from isopropyl ether (400 cc); the crystals obtained are drained, washed with isopropyl ether (40 cc) and dried.
  • the crystals obtained (5 g of the 35.6 g) are chromatographed on a silica gel column (0.2-0.063 mm, diameter 4.6 cm, height 30 cm), eluting with a mixture of cyclohexane and ethyl acetate (60/40 by volume) and collecting 100 cc fractions.
  • Fractions 4 to 10 are combined and concentrated to dryness under reduced pressure (2.7 kPa); the residue is recrystallized from acetonitrile (5 cc).
  • the aqueous solution is extracted with ethyl acetate (40 cc); the organic solutions are combined, cooled to +5° C. and acidified by addition of 4N hydrochloric acid (4 cc); the precipitate obtained is dissolved in ethyl acetate (50 cc) and the organic solution is washed with distilled water (3 ⁇ 40 cc), dried over magnesium sulphate and filtered and the filtrate is concentrated to dryness under reduced pressure (2.7 kPa). The residue, taken up in isopropyl ether (5 cc), is drained and dried.
  • (3aRS,7aRS)-2-(2-benzyloxycarbonyl-2-phenylacetyl)-7,7-diphenyl-4-perhydroisoindolone can be prepared as described above in Example 83.
  • Proton NMR spectrum At ambient temperature the mixture of the two rotamers of each of the the two diastereoisomers is observed. 1.85 to 2.3 (Mt, 2H, --CH 2 -- in 5 or 6); 2.6 to 3.2 (Mt, 4H, --CH 2 -- in 6 or 5 and --CH 2 -- in 1); 3 to 3.5 (Mt, 2H, 1H of the --CH 2 -- in 3 and --CH-- in 3a); 3.48-3.58-3.6 and 3.62 (4S, 3H in total, --COOCH 3 ); 3.65 to 4.42 (Mt, --CH-- in 7a and 1H of the --CH 2 -- in 3); 4.6-4.63-5 and 5.08 (4S, 1H in total, --N--COCH--COO--); 6.9 to 7.65 (Mt, 15H, aromatic).
  • Infrared spectrum (KBr), characteristic bands (cm -1 ): 3600-3300, 3100-3000, 3000-2800, 1745, 1715, 1650, 1600, 1580, 1495, 1475, 1445, 1400, 1195, 755, 700.
  • the reaction mixture is stirred for 2 hours at +5° C. and for 1.5 hours at 20° C. and is then diluted with ethyl acetate (250 cc) and, after filtering off the precipitate, the filtrate is washed with water (2 ⁇ 100 cc) and with saturated sodium chloride solution (100 cc) and dried over magnesium sulphate. After concentrating to dryness under reduced pressure (2.7 kPa), the residue is chromatographed on a silica gel column (0.2-0.063 mm, diameter 3.8 cm, height 31 cm), eluting under a nitrogen pressure of 0.5 bar with a mixture of cyclohexane and ethyl acetate (75/25 by volume) and collecting 25 cc fractions.
  • Proton NMR spectrum At ambient temperature the mixture of the two rotamers is observed. 1.75 to 2.35 (Mt, 2H, --CH 2 -- in 5 or 6); 2.6 to 3 (Mt, 4H, --CH 2 -- in 6 or 5 and --CH 2 -- in 1); 3.25 to 3.45 (Mt, partially masked, 1H of the --CH 2 -- in 3 and --CH-- in 3a); 3.85 to 4.15 (Mt, 1H, --CH-- in 7a); 4.25 to 4.45 (Mt, 1H, 1H of the --CH 2 -- in 3); 5.02 and 5.4 (2S, 1H in total, --N--CO--CH--N--); 6.95 to 7.65 (Mt, 14H, aromatic); 8.65 (Mf, 3H, --NH 3 + Cl - ).
  • Infrared spectrum (KBr), characteristic bands (cm -1 ): 3600-3300, 3100-3000, 3000-2850, 3150-2500, 1715, 1655, 1595, 1580, 1495, 1475, 1445, 1440, 755, 700.
  • N,N'-Carbonyldiimidazole (3.6 g) is added to a solution of (cyclohexa-1,4-dien-1-yl)acetic acid (2.35 g) in dry dichloromethane (50 cc), cooled to +5° C. The mixture is stirred for 30 minutes at +5° C. and a solution of 7,7-diphenyl-4-perhydroisoindolone hydrochloride (6.55 g) and triethylamine (5.6 cc) in dichloromethane (30 cc) is then added. The reaction mixture is stirred for 1 hour at +5° C. and then for 16 hours at 20° C.
  • Phenylacetyl chloride (0.82 cc) is added to a solution of 7,7-diphenyl-2,3,3a,4,7,7a-hexahydro-4-1H-isoindolone hydrochloride (2 g) and triethylamine (1.7 cc) in dry dichloromethane (20 cc), cooled to +5° C.
  • the reaction mixture is stirred for 1 hour at +5° C. and for 1 hour at ambient temperature; it is washed with distilled water (2 ⁇ 20 cc), dried over magnesium sulphate and filtered and the filtrate is concentrated to dryness under reduced pressure (2.7 kPa). The residue is crystallized from acetonitrile (15 cc).
  • crystlas are drained, washed with isopropyl ether (10 cc) and dried and are then recrystallized from acetonitrile (20 cc). The crystals obtained are drained and dried. (3aRS,7aRS)-7,7-diphenyl-2-phenylacetyl-2,3,3a,7,7a-hexahydro-4-1H-isoindolone (2.7 g) melting at 188° C. is obtained.
  • 7,7-Diphenyl-2,3,3a,4,7,7a-hexahydro-4-1H-isoindolone hydrochloride can be prepared in the following way:
  • 7,7-Diphenyl-2-vinyloxycarbonyl-2,3,3a,4,7,7a-hexahydro-4-1H-isoindolone (2.6 g) is stirred in a 3N solution (30 cc) of hydrochloric acid in dioxane at ambient temperature for 30 minutes; the mixture is concentrated to dryness under reduced pressure (2.7 kPa). The residue is taken up in ethanol (50 cc) and refluxed for 30 minutes; the mixture is concentrated to dryness under reduced pressure (2.7 kPa). The residue is crystallized from ethyl ether (20 cc); the crystals obtained are drained and dried. 7,7-Diphenyl-2,3,3a,4,7,7a-hexahydro-4-1H-isoindolone (2 g) melting at a temperature higher than 260° C. is obtained.
  • Trifluoroacetic acid (2 drops) is added to a solution of 4,4-diphenyl-cyclohexa-2,5-dien-1-one (7.7 g) and N-butoxymethyl-N-trimethylsilylmethylbenzylamine (11 cc) in dry dichloromethane (80 cc) and the reaction mixture is refluxed for 1 hour and a half. Additional N-butoxymethyl-N-trimethylsilylmethylbenzylamine (5 cc) and trifluoroacetic acid (2 drops) are added and the reaction mixture is heated for 1 hour and a half. The reaction mixture is treated with potassium carbonate (3 g) and filtered and the filtrate is concentrated to dryness under reduced pressure (2.7 kPa).
  • 4,4-Diphenyl-cyclohexa-2,5-dien-1-one can be prepared by the method of H. E. Zimmermann and D. I. Schuster J. Am. Chem. Soc., 84, 527 (1962).
  • Trifluoroacetic acid (3 cc) is added to a solution of 4,4-bis-(3-fluorophenyl)cyclohexenone (90.3 g) and N-butoxymethyl-N-trimethylsilylmethylbenzylamine (123 cc) in dry dichloromethane (1,000 cc).
  • the reaction mixture is brought to reflux and then stirred for 2 hours allowing the temperature to return to 25° C. and is then stirred for a further 15 minutes after addition of potassium carbonate (60 g).
  • Butenone (50.4 cc) is added to a solution of bis-(3-fluorophenyl)acetaldehyde (144.5 g) in ethyl ether (500 cc) and then, after cooling to 0° C., a solution of potassium hydroxide (13.9 g) in ethanol (89 cc) is added dropwise.
  • the reaction mixture is stirred for 2 h at 0° C. and then for 16 hours at 25° C. and diluted with ethyl acetate (300 cc) and water (500 cc).
  • the aqueous phase is washed with ethyl acetate (300 cc).
  • the organic phase is dried over magnesium sulphate and filtered and the filtrate is concentrated to dryness under reduced pressure (2.7 kPa).
  • the residue is chromatographed on a silica gel column (particle size 0.04-0.063 mm, diameter 2.2 cm, height 23 cm), eluting under a nitrogen pressure of 0.5 bar with a mixture of cyclohexane and ethyl acetate (70/30) and collecting 15 cc fractions.
  • Fractions 4 to 9 are combined and concentrated to dryness under reduced pressure (2.7 kPa) and the product obtained is recrystallized from acetonitrile. The crystals are drained, washed with isopropyl ether and dried.
  • N,N'-carbonyldiimidazole (0.59 g) is added to a solution of (2-dimethylaminophenyl)acetic acid (0.65 g) in dry dichloromethane (20 cc) cooled to +4° C. The mixture is stirred for 90 minutes at 25° C. and a solution of 7,7-bis-(3-fluorophenyl)-4-perhydroisoindolone hydrochloride (1.3 g) and triethylamine (1.02 cc) in dry dichloromethane (25 cc) is then added dropwise. The reaction mixture is stirred for 16 hours at 25° C.
  • Infrared spectrum characteristic bands in cm -1 : 3500-3150, 3100-3000, 3000-2850, 1712, 1650, 1615, 1595, 1580, 1495, 1445, 1535, 755, 700.
  • N,N-Carbonyldiimidazole (0.44 g) is added to a solution of (2-dimethylaminophenyl)acetic acid (0.49 g) in dry dichloromethane (20 cc) cooled to +4° C. The mixture is stirred for 1 hour at 25° C. and a solution of 7,7-bis-(2-fluorophenyl)-4-perhydroisoindolone hydrochloride (1 g) and triethylamine (0.76 cc) in dry dichloromethane (25 cc) is then added dropwise. The reaction mixture is stirred for 20 hours at 25° C.
  • (3aRS,7aRS)-7,7-bis-(2-Fluorophenyl)-4-perhydroisoindolone hydrochloride can be prepared in the following way: A solution of (3aRS,7aRS)-2-benzyl-7,7-bis-(2-fluorophenyl)-4-perhydroisoindolone (2.34 g) in methanol (100 cc) to which N hydrochloric acid (6.2 cc) has been added is hydrogenated under atmospheric pressure in the presence of 10% palladium-on-charcoal (0.4 g) for 5 hours at 25° C.
  • Trifluoroacetic acid (3 drops) is added to a solution of 4,4-bis-(2-fluorophenyl)-cyclohexenone (4.3 g) and N-butoxymethyl-N-trimethylsilylmethylbenzylamine (5.8 cc) in dry dichloromethane (30 cc). The reaction mixture is brought to reflux and then stirred for 16 hours after having allowed the temperature to return to 25° C. N-Butoxymethyl-N-trimethylsilymethylbenzylamine (2.5 cc) and trifluoroacetic acid (3 drops) are added and the mixture is stirred for 3 hours under reflux. The reaction mixture is treated with potassium carbonate (3 g) and stirred for 15 minutes.
  • Potassium carbonate (26.9 g) is added to a solution of bis-(2-fluorophenyl)acetaldehyde (30.8 g) in 1,2-dimethoxyethane (135 cc) and, after cooling to -50° C., butenone (19.9 cc) is then added dropwise.
  • the reaction mixture is stirred for 12 h at -50° C. and then for 6 hours at 25° C. and diluted with ethyl acetate (250 cc) and water (200 cc).
  • the organic phase is washed with water (3 ⁇ 200 cc) and then with saturated sodium chloride solution (200 cc), dried over magnesium sulphate and concentrated under reduced pressure (2.7 kPa).
  • bis-(2-Fluorophenyl)acetaldehyde can be prepared in the following way:
  • 1,2-bis-(2-Fluorophenyl)oxirane can be prepared by the method described by V. Mark (J. Am. Chem. Soc., 85, 1984 (1963)).
  • Triethylamine (0.45 cc) and then phenylacetyl chloride (0.49 g) are added to a solution of 7,7-bis-(3-chlorophenyl)-4-perhydroisoindolone hydrochloride (1.06 g) in dichloromethane (20 cc) cooled to +4° C.
  • the reactio mixture is stirred for 2 hours at 25° C. and then washed with water (3 ⁇ 30 cc) and with saturated sodium chloride solution (3 ⁇ 30 cc).
  • the organic phase is dried over magnesium sulphate and filtered and the filtrate is concentrated to dryness under reduced pressure (2.7 kPa).
  • the residue is chromatographed on a silica gel column (particle size 0.04-0.063 mm, diameter 2.2 cm, height 23 cm), eluting under a nitrogen pressure of 0.5 bar with a mixture of cyclohexane and ethyl acetate (55/45 by volume) and collecting 15 cc fractions.
  • Fractions 7 to 18 are concentrated to dryness under reduced pressure (2.7 kPa) and the residue is crystallized from acetonitrile. The crystals are drained, washed with isopropyl ether and dried.
  • 7,7-bis-(3-Chlorophenyl)-4-perhydroisoindolone hydrochloride can be prepared in the following way:
  • (3aRS,7aRS)-7,7-bis-(3-chlorophenyl)-2-vinyloxycarbonyl-4-perhydroisoindolone (1.5 g) is treated with a 6N solution (7.4 cc) of hydrochloric acid in dioxane for 2 hours at 25° C.
  • the solution is concentrated to dryness under reduced pressure (2.7 kPa) and the residue is heated for 1 hour in solution in ethanol at 60° C. and then stirred for 6 hours at 25° C.
  • the solution is concentrated to dryness under reduced pressure (2.7 kPa) and the meringue obtained is solidified in isopropyl ether.
  • the precipitate is drained and washed with isopropyl ether and then dried to give 7,7-bis-(3-chlorophenyl)-4-perhydroisoindolone hydrochloride (1 g).
  • Trifluoroacetic acid (15 drops) is added to a solution of 4,4-bis-(3-chlorophenyl)-cyclohexenone (26.8 g) and N-butoxymethyl-N-trimethylsilylmethylbenzylamine (33 cc) in dry dichloromethane (200 cc).
  • the reaction mixture is brought to reflux and then stirred for 16 hours after having allowed the temperature to return to 25° C. and for a further 15 minutes after addition of potassium carbonate (16 g).
  • Butenone (11.3 cc) is added to a solution of bis-(3-chlorophenyl)acetaldehyde (36.9 g) in ethyl ether (200 cc) and then, after cooling to 0° C., a solution of potassium hydroxide (3.1 g) in ethanol (20 cc) is added dropwise. The reaction mixture is stirred for 2 h at 0° C. and then for 16 hours at 25° C. and diluted with ethyl acetate (100 cc) and water (200 cc). The aqueous phase is washed with ethyl acetate (100 cc).
  • (3aRS,7aRS)-7,7-bis-(3-tolyl)-2-vinyloxycarbonyl-4-perhydroisoindolone (7.4 g) is treated with a 6N solution (39 cc) of hydrochloric acid in dioxane for 30 minutes at 25° C.
  • the solution is concentrated to dryness under reduced pressure (2.7 kPa) and the residue is taken up in ethanol (100 cc).
  • the solution is heated at 60° C. for 2 hours and stirred for 16 hours at 25° C. and then concentrated to dryness under reduced pressure (2.7 kPa).
  • the residue is solidified using isopropyl ether and the solid is washed, drained and dried.
  • 7,7-bis-(3-Tolyl)-4-perhydroisoindolone hydrochloride (6.36 g) is obtained in the form of a yellow solid.
  • Trifluoroacetic acid (12 drops) is added to a solution of 4,4-bis-(3-tolyl)cyclohexenone (16.7 g) and N-butoxymethyl-N-trimethylsilylmethylbenzylamine (18.7 cc) in dry dichloromethane (150 cc). The reaction mixture is brought to reflux and then stirred for 3 hours allowing the temperature to return to 25° C. and for a further 10 minutes after addition of potassium carbonate (12 g).
  • Butenone (7.23 cc) is added to a solution of bis-(3-tolyl)acetaldehyde (20.4 g) in ethyl ether (110 cc) and then, after cooling to 0° C., a solution of potassium hydroxide (2 g) in ethanol (12.7 cc) is added dropwise. The reaction mixture is stirred for 2 hours at 0° C. and then for 16 hours at 25° C. and diluted with ethyl acetate (200 cc) and water (200 cc). The aqueous phase is washed with ethyl acetate (2 ⁇ 250 cc).
  • a solution of 4,4-diphenylcyclohex-2-en-1-one (25 g) and 1,3,5-tris-trimethylsilylmethyl-1,3,5-triazine (1.65 g) in 1,1,2-trichloroethane (17 cc) is treated with a solution of phenylacetyl fluoride (1.8 g) in 1,1,2-trichloroethane (5 cc) and the mixture is then heated at 120° C. for 22 hours.
  • the reaction mixture is diluted with dichloromethane (100 cc), washed with saturated sodium bicarbonate solution (100 cc) and with saturated sodium chloride solution (100 cc), dried over magnesium sulphate and then concentrated to dryness under reduced pressure (2.7 kPa).
  • the residue is chromatographed on a silica gel column (0.2-0.063 mm, diameter 3 cm, height 27 cm), eluting with a mixture of cyclohexane and ethyl acetate (90/10 by volume) and collecting 35 cc fractions.
  • 1,3,5-tris-Trimethylsilylmethyl-1,3,5-triazine can be prepared by the method of T. Morimoto, Y. Nezu and K. Achiwa: Chem. Pharm. Bull. 33, 4596 (1985).
  • Phenylacetyl fluoride can be obtained by the method of G. Olah, S. Kuhn and S. Beke: Chem. Ber. 89, 862, (1956).
  • Isopropyl iodide (0.34 cc) and potassium carbonate (0.89 g) are added to a solution of (3aRS,7aRS)-2-[(2-hydroxyphenyl)acetyl]-7,7-diphenyl-4-perhydroisoindolone (1.3 g) in butanone (26 cc) and dimethylformamide (1.3 cc).
  • the mixture is refluxed for 6 hours and then cooled to ambient temperature.
  • the solid is removed by filtration and washed with butanone (2 ⁇ 10 cc).
  • the organic fractions are collected, dried over magnesium sulphate and concentrated under reduced pressure.
  • the residue is chromatographed on a column of silica gel (150 g) eluting with a mixture of cyclohexane and ethyl acetate (80/20 by volume).
  • the residue is taken up in methylene chloride (5 cc) and water (5 cc).
  • the organic phase is decanted, washed with [lacuna] (2 ⁇ 5 cc), dried over sodium sulphate and evaporated under reduced pressure.
  • the residue is crystallized from petroleum ether (b.p. 40° C.-60° C.) (50 cc). The crystals are drained, washed with petroleum ether and dried.
  • the reaction mixture is refluxed for 21 hours and then treated with acetic acid (0.35 cc), diluted with water (20 cc) and ethyl acetate (20 cc).
  • the organic phase is extracted with 0.2N hydrochloric acid (2 ⁇ 30 cc).
  • the acid aqueous phase is washed with ethyl acetate, rendered alkaline by addition of N sodium hydroxide solution (25 cc), and reextracted with ethyl acetate.
  • the organic phase is washed with water until neutral, dried over magnesium sulphate and concentrated to dryness under reduced pressure (2.7 kPa).
  • the reaction mixture is refluxed for 16 hours and then treated with acetic acid (0.5 cc) and diluted with water (20 cc) and ethyl acetate (50 cc).
  • the organic phase is extracted with 0.2N hydrochloric acid (2 ⁇ 25 cc).
  • the acid aqueous phase is washed with ethyl acetate and filtered and the filtrate is concentrated to dryness under reduced pressure (2.7 kPa).
  • the residue is dissolved in ethyl acetate (20 cc) and treated with a 3M solution (1.2 cc) of hydrochloric acid in dry dioxane.
  • the expected product precipitates in the form of the impure hydrochloride.
  • Infrared spectrum (KBr), characteristic bands (cm -1 ): 3600-3250, 3100-3000, 3000-2850, 2750, 2250, 1715, 1640, 1600, 1495, 1475, 1455, 1445, 1440, 1245, 1050, 755, 705.
  • (3aRS,7aRS)-2-[(2-hydroxyphenyl)acetyl]-7,7-diphenyl-4-perhydroisoindolone (2.55 g) is added to a suspension of sodium hydride (0.32 g) (50% dispersion in oil) in toluene (10 cc) and, at 25° C., a solution of 1-(4-methyl-1-piperazinyl)-2-chloroethane in dry toluene (10 cc) (obtained by liberation from the corresponding dihydrochloride (1.14 g) by the action of caustic potash) is then added.
  • the reaction mixture is refluxed for 18 hours and then treated with water (20 cc) and ethyl acetate (30 cc).
  • the aqueous phase is extracted with ethyl acetate (10 cc) and the combined organic phases are washed with water until neutral, dried over sodium sulphate and concentrated to dryness under reduced pressure (2.7 kPa).
  • the residue is washed with petroleum ether and then dissolved in a mixture of ethyl acetate and dilute methanesulphonic acid (pH 2).
  • the organic phase is washed with water and the combined acid aqueous phases are washed with ethyl acetate and neutralized by the action of normal sodium hydroxide solution.
  • 1-(4-Methyl-1-piperazinyl)-2-chloroethane dihydrochloride is prepared by the method of G. Emptoz et al., Chim. Ther., 4 (4), 283 (1969).
  • Ethyl phenylacetimidate hydrobromide (1.2 g) and triethylamine (1.4 cc) are added to a stirred suspension of (3aRS,7aRS)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (1.6 g) in 1,2-dichloroethane (40 cc). Stirring of the reaction mixture is continued for 20 hours at ambient temperature and then for 6 hours under reflux. After the temperature has returned to ambient temperature, the reaction mixture is treated with a saturated aqueous solution (50 cc) of potassium carbonate; the organic phase is dried over magnesium sulphate and filtered and the filtrate is concentrated to dryness under reduced pressure (2.7 kPa).
  • Ethyl phenylacetimidate hydrobromide can be prepared by a method described by D. J. Morgan, Chem. and Ind., 854 (1959).
  • Triethyloxonium tetrafluoborate (8.4 g) is added to a stirred suspension of 2-(2-methoxyphenyl)acetamide (6.6 g) in anhydrous dichloromethane (20 cc). Stirring of the reaction mixture is continued for 20 hours at ambient temperature. The mixture is cooled to +5° C. and a solution of (3aR,7aR)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (9.8 g) and triethylamine (10.4 cc) in dichloromethane (60 cc) is then added. After the temperature has returned to ambient temperature, the reaction mixture is refluxed for 4 hours.
  • 2-(2-Methoxyphenyl)acetamide can be prepared by the method described by U.S. Seth and S. S. Deshapande, J. Indian Chem. Soc., 27, 429 (1950).
  • Infrared spectrum (characteristic bands): 3425, 3100-3000, 3000-2850, 2835, 1715, 1592, 1610, 1595, 1460, 1250, 1030, 780, 755, 695.
  • Triethyloxonium tetrafluoborate (6.34 g) is added to a stirred suspension of (RS)-2-(2-methoxyphenyl)propionamide (5.4 g) in anhydrous dichloromethane (60 cc). The reaction mixture is stirred for 20 hours. A solution of (3aR,7aR)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (6.65 g) and triethylamine (2.8 cc) in dichloromethane (30 cc) is added. The reaction mixture is refluxed for 5 hours. It is then cooled to +5° C. and is then treated with a 10% aqueous potassium carbonate solution (20 cc).
  • the organic phase is washed with distilled water (20 cc), dried over magnesium sulphate and concentrated to dryness under reduced pressure (2.7 kPa).
  • the residue is chromatographed on a neutral alumina column (0.05 mm-0.160 mm, diameter 5 cm, height 20 cm), eluting with a mixture of cyclohexane and ethyl acetate (50/50) and collecting 250 cc fractions.
  • the first fraction is concentrated to dryness under reduced pressure (2.7 kPa).
  • the residue is chromatographed on a silica gel column (0.04 mm-0.06 mm, diameter 2 cm, height 35 cm), eluting with a mixture of n-butanol/acetic acid/pyridine/water (90/4/4/2 by volume) and collecting 20 cc fractions. Fractions 14 to 19 are concentrated to dryness under reduced pressure (0.13 kPa). The residue is taken up in dichloromethane (40 cc) and washed with aqueous potassium carbonate solution (10 cc). The organic phase is dried over magnesium sulphate and concentrated to dryness under reduced pressure (2.7 kPa). The residue is crystallized from diisopropyl ether.
  • Infrared spectrum (KBr), characteristic bands (cm -1 ): 3400, 3100-3000, 3000-2850, 2835, 1715, 1595, 1495, 1445, 1245, 1030, 750, 700.
  • form B (0.1 g) is obtained in the form of a white meringue from the combined chromatographic fractions 21 to 30.
  • N,N'-Carbonyldiimidazole (16.2 g) is added to a solution of 2-(2-methoxyphenyl)propionic acid (17.5 g) in dry dichloromethane (200 cc), cooled to +5° C. The mixture is stirred for 30 minutes at +5° C. and a stream of ammonia is then passed into the solution for 1 hour, maintaining the same temperature. After stirring for 2 hours at 20° C., the reaction mixture is washed with water (200 cc), dried over magnesium sulphate and then concentrated to dryness under reduced pressure (2.7 kPa). The residue is crystallized from isopropyl ether and the crystals are drained and dried under reduced pressure (2.7 kPa).
  • (RS)-2-(2-Methoxyphenyl)propionamide (12.1 g) is obtained in the form of a white solid melting at 138° C.
  • a 1.6M solution (20 cc) of n-butyllithium in tetrahydrofuran is added in the course of 20 minutes to a solution of diisopropylamine (45.5 cc) in tetrahydrofuran (250 cc), cooled to +10° C. After stirring for 10 minutes, the mixture is brought to 0° C. and a solution of 2-(2-methoxyphenyl)acetic acid in tetrahydrofuran (100 cc) is added in the course of 20 minutes. After 30 minutes at 35° C., methyl iodide (10 cc) is added and the mixture is stirred for 1 hour at 35° C.
  • Triethoxyloxonium tetrafluoroborate (4 g) is added to a stirred solution of N-(2-thienyl)methyl-2-(2-methoxyphenyl)acetamide (5.2 g) in anhydrous dichloromethane (50 cc). Stirring of the reaction mixture is continued for 7 hours, at ambient temperature. The mixture is cooled to +5° C. and a solution of (3aR,7aR)-7,7-diphenyl-4-perhydroisoindolone hydrochloride (4.6 g) and triethylamine (5 cc) in dichloromethane (50 cc) is then added.
  • N-(2-Thienyl)methyl-2-(2-methoxyphenyl)acetamide can be prepared in the following way:
  • N,N'-Carbonyldiimidazole (8.1 g) is added to a stirred solution of 2-(2-methoxyphenyl)acetic acid (8.3 g) in anhydrous dichloromethane (80 cc), cooled to +5° C.; stirring of the reaction mixture is continued for 1 hour and a half and (2-thienyl)methylamine (5.1 cc) is then added. Stirring of the reaction mixture is continued for 1 hour at +5° C. and then for 2 hours at ambient temperature. The reaction mixture is then washed with distilled water (2 ⁇ 40 cc); the organic solution is dried over magnesium sulphate and concentrated to dryness under reduced pressure (2.7 kPa).
  • the present invention also relates to the pharmaceutical compositions consisting of a product of general formula (I), or a salt where such exist, optionally in combination with any other pharmaceutically compatible product, which can be inert or physiologically active.
  • the compositions according to the invention can be administered parenterally, orally or rectally or applied topically.
  • the sterile compositions for parenteral administration which can be used, in particular, in the form of perfusions are preferably aqueous or non-aqueous solutions or suspensions or emulsions.
  • the solvent or vehicle used can be water, propylene glycol, a polyethylene glycol, vegetable oils, in particular olive oil, injectable organic esters, for example ethyl oleate, or other suitable organic solvents.
  • These compositions may also contain adjuvants, in particular wetting agents, agents for rendering isotonic, emulsifiers, dispersants and stabilizers.
  • Sterilization can be effected in various ways, for example by aseptizing filtration, by incorporating sterilizing agents into the composition, by irradiation or by heating. They may also be prepared in the form of sterile solid compositions which can be dissolved at the time of use in an injectable sterile medium.
  • compositions for rectal administration are suppositories or rectal capsules which contain, in addition to the active product, excipients such as cacao butter, semi-synthetic glycerides or polyethylene glycols.
  • compositions for oral administration which can be used are tablets, pills, powders or granules.
  • the active product according to the invention (optionally in combination with another pharmaceutically compatible product) is mixed with one or more inert diluents or adjuvants, such as sucrose, lactose or starch.
  • these compositions may also comprise substances other than the diluents, for example a lubricant, such as magnesium stearate.
  • Liquid compositions for oral administration which can be used are pharmaceutically acceptable emulsions or solutions, suspensions, syrups and elixirs containing inert diluents such as water or paraffin oil. These compositions may also comprise substances other than the diluents, for example wetting agents, sweeteners or flavorings.
  • compositions for topical application can be, for example, creams, ointments or lotions.
  • the products according to the invention can be particularly useful in the treatment of pain of traumatic, post-surgical, menstrual or cephalic origin, in the treatment of anxiety, psychoses, Parkinson's disease, schizophrenia or Alzheimer's disease, in muscle-relaxing treatments, in the treatment of spasmodic, painful and inflammatory occurrences in the digestive tracts (ulcerous colites, irritable colon syndrome, Crohn's disease), of the urinary tract (cystites) and of the respiratory tract (asthma, rhinites) or in gynaecology and in the treatment of migraine.
  • the new isoindolone derivatives are also useful in the treatment of rheumatoid arthritis and in disorders due to disturbance of the immune system, in the treatment of inflammation in dermatology, such as psoriasis, herpes, urticarias, eczemas and photodermates, and in occular and dental inflammatory disorders.
  • the products according to the invention can also find application in the treatment of cardiovascular disorders, such as hypotension.
  • the dosages depend on the desired effect and on the duration of the treatment. For an adult, they are generally between 0.25 and 1500 mg per day taken at intervals.
  • the physician will determine the posology, which he estimates most appropriately as a function of the age, the body weight and all of the other factors inherent to the subject to be treated.
  • active product tablets having the following composition are prepared:

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
US07/616,262 1989-11-23 1990-11-20 Isoindolone derivatives, their preparation and the pharmaceutical compositions containing them Expired - Fee Related US5102667A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8915406 1989-11-23
FR8915406A FR2654725B1 (fr) 1989-11-23 1989-11-23 Nouveaux derives de l'isoindolone, leur preparation et les compositions pharmaceutiques qui les contiennent.

Publications (1)

Publication Number Publication Date
US5102667A true US5102667A (en) 1992-04-07

Family

ID=9387707

Family Applications (1)

Application Number Title Priority Date Filing Date
US07/616,262 Expired - Fee Related US5102667A (en) 1989-11-23 1990-11-20 Isoindolone derivatives, their preparation and the pharmaceutical compositions containing them

Country Status (23)

Country Link
US (1) US5102667A (fi)
EP (1) EP0429366B1 (fi)
JP (1) JPH03176469A (fi)
KR (1) KR910009659A (fi)
AT (1) ATE102923T1 (fi)
AU (1) AU635361B2 (fi)
CA (1) CA2030569A1 (fi)
DE (1) DE69007429T2 (fi)
DK (1) DK0429366T3 (fi)
ES (1) ES2062460T3 (fi)
FI (1) FI905769A (fi)
FR (1) FR2654725B1 (fi)
HU (1) HUT56064A (fi)
IE (1) IE904235A1 (fi)
IL (1) IL96446A0 (fi)
NO (1) NO174387C (fi)
NZ (1) NZ236176A (fi)
PL (4) PL164909B1 (fi)
PT (1) PT95982A (fi)
RU (1) RU2012559C1 (fi)
TW (1) TW218378B (fi)
YU (1) YU223490A (fi)
ZA (1) ZA909369B (fi)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360820A (en) * 1991-09-20 1994-11-01 Glaxo Group Limited Medical use for tachykinin antagonists
US5451601A (en) * 1991-05-17 1995-09-19 Rhone-Poulenc Rorer S.A. Perhydroisoindole derivatives and pharmaceutical compositions containing them
US5463077A (en) * 1992-04-10 1995-10-31 Rhone-Poulenc Rorer S.A. Perhydroisoindole derivatives and preparation
US5491140A (en) * 1994-06-30 1996-02-13 Eli Lilly And Company Naphthyl tachykinin receptor antagonists to treat physiological conditions
US5508433A (en) * 1991-05-17 1996-04-16 Rhone-Poulenc Rorer S.A. Derivatives of perhydroisoindole and preparation thereof
US5547964A (en) * 1993-03-19 1996-08-20 Glaxo Group Limited Medical use for tachykinin antagonists
US5589489A (en) * 1993-12-15 1996-12-31 Zeneca Limited Cyclic amide derivatives for treating asthma
US5624950A (en) * 1993-07-30 1997-04-29 Rhone-Poulenc Rorer S.A. Perhydroisoindole derivatives as substance P antagonists
US5631279A (en) * 1993-04-05 1997-05-20 Rhone-Poulenc Rorer, S.A. Perhydroisoindole derivatives, preparation thereof and pharmaceutical compositions containing same
US5670499A (en) * 1993-11-17 1997-09-23 Eli Lilly And Company Non-peptide tachykinin receptor antagonists
US5965562A (en) * 1994-10-14 1999-10-12 Novartis Corporation Aroyl-piperidine derivatives
US6184380B1 (en) * 1999-01-25 2001-02-06 Pfizer Inc. Process for preparing naphthyridones and intermediates
US20020059239A1 (en) * 2000-11-10 2002-05-16 Masae Yanagi Data managing method, data managing system, data managing apparatus, data handling apparatus, computer program, and recording medium
US20020095043A1 (en) * 1998-01-16 2002-07-18 Chiu Charles K. Process for preparing naphthyridones and intermediates
US6869957B1 (en) 1993-11-17 2005-03-22 Eli Lilly And Company Non-peptide tachykinin receptor antagonists
US20050234061A1 (en) * 2002-03-12 2005-10-20 Hagmann William K Substituted amides
US20060040975A1 (en) * 2004-04-07 2006-02-23 Schering Corporation Fused ring NK1 antagonists
WO2010000073A1 (en) 2008-07-03 2010-01-07 Neuraxon, Inc. Benzoxazines, benzothiazines, and related compounds having nos inhibitory activity
US8013172B2 (en) 2006-02-21 2011-09-06 Bayer Cropscience Ag Cycloalkylphenyl substituted cyclic ketoenols
CN114835652A (zh) * 2022-06-02 2022-08-02 河南大学 一种光催化条件下合成亚胺基苯并三唑类化合物的方法

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
FR2688219B1 (fr) 1992-03-03 1994-07-08 Sanofi Elf Sels d'ammonium quaternaires de composes aromatiques amines, leur preparation et compositions pharmaceutiques les contenant.
FR2689888B1 (fr) * 1992-04-10 1994-06-10 Rhone Poulenc Rorer Sa Nouveaux derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent.
US5830854A (en) * 1992-12-14 1998-11-03 Merck Sharp & Dohme, Limited Method of treating cystic fibrosis using a tachykinin receptor antagonist
FR2709752B1 (fr) * 1993-07-30 1995-10-06 Rhone Poulenc Rorer Sa Nouveaux dérivés de perhydroisoindole, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2710913B1 (fr) * 1993-10-07 1995-11-24 Rhone Poulenc Rorer Sa Nouveaux dérivés de perhydroisoindole, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2710842B1 (fr) * 1993-10-07 1995-11-24 Rhone Poulenc Rorer Sa Nouvelle application thérapeutique de dérivés de perhydroisoindole.
US6203803B1 (en) 1994-12-14 2001-03-20 Societe L'oreal S.A. Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
FR2719476B1 (fr) * 1994-05-05 1997-05-23 Oreal Utilisation d'un antagoniste de substance P dans une composition cosmétique et composition obtenue.
FR2719474B1 (fr) * 1994-05-05 1996-05-31 Oreal Utilisation d'un antagoniste de substance P dans une composition cosmétique et composition obtenue.
FR2725900B1 (fr) * 1994-10-21 1997-07-18 Sanofi Sa Utilisation d'antagonistes des recepteurs nk1 pour la preparation de medicaments a action cardioregulatrice
FR2728166A1 (fr) 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
FR2728165A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
FR2728169A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
FR2741262B1 (fr) 1995-11-20 1999-03-05 Oreal Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
BR0015320A (pt) 1999-11-03 2002-07-09 Albany Molecular Res Inc Composto, composição, métodos de tratamento de um distúrbio que e criado pela, ou é dependente da, disponibilidade diminuìda de serotonina, norepinefrina ou dopamina, para inibir a captação da serotonina, da dopamina e de norepinefrina sinápticas em um paciente em necessidade destes, e, kit
CN100430401C (zh) 2000-07-11 2008-11-05 Amr科技公司 新的4-苯基取代的四氢异喹啉类化合物及其治疗用途
UA91341C2 (ru) 2004-07-15 2010-07-26 Амр Текнолоджи, Інк. Арил- и гетероарилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
JP5258561B2 (ja) 2005-07-15 2013-08-07 アルバニー モレキュラー リサーチ， インコーポレイテッド アリール置換およびヘテロアリール置換テトラヒドロベンズアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
JP4611444B2 (ja) 2007-01-10 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール
JP2010516731A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド ２−メトキシ−５−（５−トリフルオロメチル−テトラゾール−１−イル）−ベンジル］−（２ｓ−フェニル−ピペリジン−３ｓ−イル）−アミンを含む医薬組成物
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
AU2010247849B2 (en) 2009-05-12 2015-11-19 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
US8815894B2 (en) 2009-05-12 2014-08-26 Bristol-Myers Squibb Company Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
EP2429296B1 (en) 2009-05-12 2017-12-27 Albany Molecular Research, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
JP5099731B1 (ja) 2009-10-14 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション ｐ５３活性を増大する置換ピペリジン及びその使用
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
US9029341B2 (en) 2010-08-17 2015-05-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
WO2012027236A1 (en) 2010-08-23 2012-03-01 Schering Corporation NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
US20140045832A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Insulin-Like Growth Factor-1 Receptor Inhibitors
EP2729147B1 (en) 2011-07-04 2017-09-06 IRBM - Science Park S.p.A. Nk-1 receptor antagonists for treating corneal neovascularisation
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2844261B1 (en) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
CA2882950A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
MX363243B (es) 2012-11-28 2019-03-14 Merck Sharp & Dohme Composiciones para tratar cáncer y usos de dichas composiciones.
TW201429969A (zh) 2012-12-20 2014-08-01 Merck Sharp & Dohme 作爲ｈｄｍ２抑制劑之經取代咪唑吡啶
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
EP3525785A4 (en) 2016-10-12 2020-03-25 Merck Sharp & Dohme Corp. KDM5 INHIBITORS
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
RU2020131446A (ru) 2018-02-26 2022-03-28 Оспедале Сан Раффаэле С.Р.Л. Антагонисты nk-1 для применения в лечении глазной боли
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
CN112805006B (zh) 2018-08-07 2024-09-24 默沙东有限责任公司 Prmt5抑制剂
EP4117673A1 (en) 2020-03-11 2023-01-18 Ospedale San Raffaele S.r.l. Treatment of stem cell deficiency

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3890347A (en) * 1971-12-08 1975-06-17 Allen & Hanburys Ltd Isoindoline derivatives
US4042707A (en) * 1976-02-19 1977-08-16 E. I. Du Pont De Nemours And Company 3α-Arylhydroisoindoles

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3890347A (en) * 1971-12-08 1975-06-17 Allen & Hanburys Ltd Isoindoline derivatives
US4042707A (en) * 1976-02-19 1977-08-16 E. I. Du Pont De Nemours And Company 3α-Arylhydroisoindoles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
European Search Report, dated Feb. 8, 1990. *

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508433A (en) * 1991-05-17 1996-04-16 Rhone-Poulenc Rorer S.A. Derivatives of perhydroisoindole and preparation thereof
US5451601A (en) * 1991-05-17 1995-09-19 Rhone-Poulenc Rorer S.A. Perhydroisoindole derivatives and pharmaceutical compositions containing them
US7342028B2 (en) 1991-09-20 2008-03-11 Glaxo Group Limited Medical use for tachykinin antagonists
US7214692B2 (en) 1991-09-20 2007-05-08 Glaxo Group Limited Medical use for tachykinin antagonists
US5360820A (en) * 1991-09-20 1994-11-01 Glaxo Group Limited Medical use for tachykinin antagonists
US5538982A (en) * 1991-09-20 1996-07-23 Glaxo Group Limited Medical use for tachykinin antagonists
US20020052351A1 (en) * 1991-09-20 2002-05-02 Glaxo Group Limited Novel medical use for tachykinin antagonists
US20050085414A1 (en) * 1991-09-20 2005-04-21 Glaxo Group Limited Novel medical use for tachykinin antagonists
US5798363A (en) * 1991-09-20 1998-08-25 Glaxo Group Limited Use for tachykinin antagonists to treat emesis
US5463077A (en) * 1992-04-10 1995-10-31 Rhone-Poulenc Rorer S.A. Perhydroisoindole derivatives and preparation
US6329394B1 (en) 1993-03-19 2001-12-11 Glaxo Group Limited Medical use for tachykinin antagonists
US5547964A (en) * 1993-03-19 1996-08-20 Glaxo Group Limited Medical use for tachykinin antagonists
US5631279A (en) * 1993-04-05 1997-05-20 Rhone-Poulenc Rorer, S.A. Perhydroisoindole derivatives, preparation thereof and pharmaceutical compositions containing same
US5624950A (en) * 1993-07-30 1997-04-29 Rhone-Poulenc Rorer S.A. Perhydroisoindole derivatives as substance P antagonists
US6403577B1 (en) 1993-11-17 2002-06-11 Eli Lilly And Company Hexamethyleneiminyl tachykinin receptor antagonists
US5670499A (en) * 1993-11-17 1997-09-23 Eli Lilly And Company Non-peptide tachykinin receptor antagonists
US5684033A (en) * 1993-11-17 1997-11-04 Eli Lilly And Company Non-peptide tachykinin receptor antagonists
US6869957B1 (en) 1993-11-17 2005-03-22 Eli Lilly And Company Non-peptide tachykinin receptor antagonists
US6727255B1 (en) 1993-11-17 2004-04-27 Eli Lilly And Company Piperidinyl and piperazinyl tachykinin receptor antagonists
US5589489A (en) * 1993-12-15 1996-12-31 Zeneca Limited Cyclic amide derivatives for treating asthma
US5705505A (en) * 1993-12-15 1998-01-06 Zeneca Limited Cyclic amide derivatives for treating asthma
US5491140A (en) * 1994-06-30 1996-02-13 Eli Lilly And Company Naphthyl tachykinin receptor antagonists to treat physiological conditions
US5965562A (en) * 1994-10-14 1999-10-12 Novartis Corporation Aroyl-piperidine derivatives
US20020095043A1 (en) * 1998-01-16 2002-07-18 Chiu Charles K. Process for preparing naphthyridones and intermediates
US7019142B2 (en) 1998-01-16 2006-03-28 Pfizer Inc. Process for preparing naphthyridones and intermediates
US6184380B1 (en) * 1999-01-25 2001-02-06 Pfizer Inc. Process for preparing naphthyridones and intermediates
US20020059239A1 (en) * 2000-11-10 2002-05-16 Masae Yanagi Data managing method, data managing system, data managing apparatus, data handling apparatus, computer program, and recording medium
US7043496B2 (en) 2000-11-10 2006-05-09 Masae Yanagi Data managing method, data managing system, data managing apparatus, data handling apparatus, computer program, and recording medium
US7550489B2 (en) 2002-03-12 2009-06-23 Merck & Co., Inc. Substituted pyridyoxy amides
US20080171692A1 (en) * 2002-03-12 2008-07-17 Hagmann William K Substituted amides
US20050234061A1 (en) * 2002-03-12 2005-10-20 Hagmann William K Substituted amides
US20090258884A1 (en) * 2002-03-12 2009-10-15 Hagmann William K Substituted amides
US7816534B2 (en) 2002-03-12 2010-10-19 Merck Sharp & Dohme Corp. Substituted amides
US20060040975A1 (en) * 2004-04-07 2006-02-23 Schering Corporation Fused ring NK1 antagonists
US7498438B2 (en) 2004-04-07 2009-03-03 Schering Corporation Fused ring NK1 antagonists
US8013172B2 (en) 2006-02-21 2011-09-06 Bayer Cropscience Ag Cycloalkylphenyl substituted cyclic ketoenols
US8541617B2 (en) 2006-02-21 2013-09-24 Bayer Cropscience Ag Cycloalkylphenyl substituted cyclic ketoenols
WO2010000073A1 (en) 2008-07-03 2010-01-07 Neuraxon, Inc. Benzoxazines, benzothiazines, and related compounds having nos inhibitory activity
CN114835652A (zh) * 2022-06-02 2022-08-02 河南大学 一种光催化条件下合成亚胺基苯并三唑类化合物的方法
CN114835652B (zh) * 2022-06-02 2023-11-03 河南大学 一种光催化条件下合成亚胺基苯并三唑类化合物的方法

Also Published As

Publication number Publication date
RU2012559C1 (ru) 1994-05-15
ATE102923T1 (de) 1994-04-15
EP0429366B1 (fr) 1994-03-16
AU6683890A (en) 1991-05-30
PL164909B1 (pl) 1994-10-31
PL292279A1 (en) 1992-06-01
KR910009659A (ko) 1991-06-28
TW218378B (fi) 1994-01-01
HU907250D0 (en) 1991-05-28
PL292280A1 (en) 1992-06-01
PL164892B1 (pl) 1994-10-31
HUT56064A (en) 1991-07-29
DE69007429D1 (de) 1994-04-21
NO905066D0 (no) 1990-11-22
YU223490A (sh) 1993-05-28
PL164904B1 (pl) 1994-10-31
PT95982A (pt) 1991-09-13
AU635361B2 (en) 1993-03-18
NO905066L (no) 1991-05-24
NO174387C (no) 1994-04-27
EP0429366A1 (fr) 1991-05-29
JPH03176469A (ja) 1991-07-31
PL292278A1 (en) 1992-06-01
IL96446A0 (en) 1991-08-16
NO174387B (no) 1994-01-17
NZ236176A (en) 1993-05-26
DK0429366T3 (da) 1994-06-27
DE69007429T2 (de) 1994-07-07
FI905769A (fi) 1991-05-24
ES2062460T3 (es) 1994-12-16
ZA909369B (en) 1991-10-30
FR2654725A1 (fr) 1991-05-24
CA2030569A1 (fr) 1991-05-24
FR2654725B1 (fr) 1992-02-14
FI905769A0 (fi) 1990-11-22
IE904235A1 (en) 1991-06-05
PL164900B1 (pl) 1994-10-31

Similar Documents

Publication Publication Date Title
US5102667A (en) Isoindolone derivatives, their preparation and the pharmaceutical compositions containing them
AU653033B2 (en) Novel derivatives of thiopyranopyrrole, their preparation and pharmaceutical compositions containing them
US5484804A (en) Perhydroisoindole derivatives as antagonists of substance P
US5451601A (en) Perhydroisoindole derivatives and pharmaceutical compositions containing them
US5112988A (en) Isoindolone derivatives
US5739351A (en) Perhydroisoindole derivatives as substance P antagonists
US5624950A (en) Perhydroisoindole derivatives as substance P antagonists
WO2000000472A1 (en) 5-ht7 receptor antagonists
US5463077A (en) Perhydroisoindole derivatives and preparation
US5631279A (en) Perhydroisoindole derivatives, preparation thereof and pharmaceutical compositions containing same
FR2709752A1 (fr) Nouveaux dérivés de perhydroisoindole, leur préparation et les compositions pharmaceutiques qui les contiennent.

Legal Events

Date Code Title Description
AS Assignment

Owner name: RHONE-POULENC SANTE, 20, AVENUE RAYMOND ARON, F 92

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:DUBROEUCQ, MARIE-CHRISTINE;MOUTONNIER, CLAUDE;PEYRONEL, JEAN-FRANCOIS;AND OTHERS;REEL/FRAME:005526/0433

Effective date: 19901115

FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
FP Lapsed due to failure to pay maintenance fee

Effective date: 20000407

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362